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ABSTRACT OF DISSERTATION

POPULATION PHARMACOKINETIC MODELING AND GENETIC ASSOCIATION
ANALYSIS IN INFANTS WITH NEONATAL ABSTINENCE SYNDROME
RECEIVING MORPHINE OR CLONIDINE
Neonatal abstinence syndrome, or NAS, is a postnatal opioid withdrawal syndrome
occurring in 55% to 94% of neonates as a result of in utero exposure to opioids. It has
emerged as a significant public health issue, as its incidence more than quadrupled in the
past decade. There is significant variability in disease severity and treatment outcomes in
neonates with NAS due to patient-specific factors and treatment- or site-specific factors.
To understand what contributes to variability in length of hospital stay and other outcomes
in neonates with NAS, we assessed population pharmacokinetics (PK) of clonidine and
morphine, and we investigated potential associations between pre-specified single
nucleotide polymorphisms (SNPs) and PK or disease severity/outcome measures.
Samples collected from neonates enrolled in the No-POPPY trial (NCT03396588)
up to early 2020 were used for analysis. PK samples from treated subjects on oral morphine
or oral clonidine were analyzed for morphine, morphine-3-glucuronide, morphine-6glucuronide and clonidine concentrations by LC-MS/MS. DNA was isolated from lysed
whole blood or buccal swabs from treated and non-treated subjects and analyzed by
TaqMan SNP genotyping assays using real-time PCR. Genetic association analysis was
performed on COMT 472G>A and OPRM1 118A>G in all trial subjects, and on GNB3
825C>T and ADRA2A -1291G>C in clonidine-treated subjects. NONMEM (ver 7.3) was
used to build population PK models and identify covariates associated with PK variability,
including SNPs potentially associated with PK of morphine/clonidine (OCT1*2-*5,
ABCC3 -211C>T, and CYP2D6 metabolizer class).
In the genetic association analysis, in contrast to a previous report, the relationship
between COMT 472G>A or OPRM1 118A>G and hospital length of stay or other outcome
measures was inconclusive. Clonidine-treated patients with TT genotype in GNB3 825C>T
had an average length of stay that was 3.7 days shorter than those with CC/CT genotypes
(p=0.045), which did not meet experiment-wise significance. Significant associations
between several clinical factors and one or more measures of NAS severity were identified,
including breastfeeding and maternal use of benzodiazepines and gabapentin during
pregnancy. In the population PK analysis, one-compartment models, with allometric
scaling incorporated a priori, were used for clonidine and morphine. Age was a significant

covariate in both models, and a sigmoidal maturation model incorporating postnatal age on
clearance provided a good fit to clonidine concentration data. The clonidine PK model was
successfully used to simulate alternative initial dosing regimens that were more likely to
achieve earlier symptom stabilization. Genetic factors evaluated in the population PK
analysis did not significantly affect the disposition of clonidine or morphine. Within the
scope of this project, clinical factors appeared to be more important factors affecting
disposition of treatment agents and NAS severity/treatment outcomes than the genetic
factors evaluated. As the next step, efforts will be made to extend current analysis as the
clinical trial continues to enroll subjects.
KEYWORDS: Neonatal abstinence syndrome, substance abuse, clonidine, morphine,
population pharmacokinetics, genetic association analysis
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CHAPTER 1. BACKGROUND
1.1

Neonatal Abstinence Syndrome (NAS)
Neonatal abstinence syndrome or NAS, a postnatal opioid withdrawal syndrome

that occurs in 55% to 94% of neonates due to in utero exposure to opioids, has emerged as
a significant public health issue.1-4 The sharp increase in NAS incidence in the last decade
from 1.2 to 5.8 for every 1,000 hospital births can be ascribed to a rise in the use of
prescribed or illicit opioids and the expansion in opioid-substitution programs in pregnant
women with opioid dependence.3,5 Between 2005 and 2011, over 14% of pregnant women
received an opioid prescription during their pregnancy.6 The 2013 National Survey on
Drug Use and Health reported that in 2012-2013 the percentage of illicit drug use was 5.4%
in pregnant women aged 15-44, but this percentage was as high as 14.6% and 8.6% in
pregnant women aged 15-17 and 18-25, respectively.7 NAS is characterized by
hyperactivity of central nervous system (CNS) and dysregulation of autonomic nervous
system.8-10 Neonates with NAS exhibit symptoms that range from tremors, poor feeding,
irritability, to increased muscle tone, fever, and seizures,11 and these newborns are more
likely to have low birth weight and respiratory complications than other newborns.12
The significant growth in the incidence of NAS in recent years corresponded to a
significant upward trend in associated national healthcare expenditures. A retrospective
study using national databases demonstrated that the mean hospital charges for neonates
with NAS increased from $39,400 to $53,400 from 2000 to 2009, with majority of the
charges paid by state Medicaid programs.12 The same study reported that the length of
hospitalization for NAS averaged 16 days, which remained unchanged in the study
period.12 On the other hand, Tolia et al. reported that in the neonatal intensive care unit
1

(NICU) setting, the median hospital stay increased from 13 days to 19 days from 2004 to
2013 across 299 NICUs in the US.13 Consequently, there is a need to improve the
effectiveness and efficiency of NAS treatment, decrease the length of hospitalization of
these newborns and consequently reduce associated healthcare expenditures.

1.2

Management of NAS
There exists significant variability in disease severity in NAS, which makes it

impossible to predict which opioid-exposed neonates will need pharmacologic
management, and which will have a more severe phenotype and require prolonged
treatment with one or more pharmacologic agents. Therefore, it is necessary to monitor all
opioid-exposed infants in hospital for 4-7 days after birth.14
Nonpharmacologic therapy is indicated as initial treatment in all cases, and
examples of nonpharmacologic treatment include decreasing environmental stimuli,
swaddling, rocking, swaying, and giving small and frequent feedings of hypercaloric
formula or human milk.11,15 A number of studies have demonstrated the benefits of
nonpharmacologic interventions, including rooming-in by parents and breastfeeding, on
reducing the need for treatment and/or length of hospital stay.16-22
Patients’ withdrawal scores based on abstinence scoring systems, such as the most
widely used Finnegan Neonatal Abstinence Scoring Tool, can be used to support the
decision to start pharmacologic intervention in patients who have moderate to severe
symptoms and/or fail to respond to nonpharmacologic management, and to guide dosing
escalation/de-escalation in these patients.11,23,24 These neonates typically receive
replacement opioids and get weaned off after days to weeks.3,11 However, it must be noted
that the clearly proven benefit of pharmacologic treatment is limited to short-term
2

symptomatic relief.11 Unnecessary pharmacologic intervention may lead to prolonged
exposure to drugs and hospital stay, and it is unclear whether it may increase the risk of
neurobehavioral complications resulted from intrauterine exposure.11
A study on the incidence of NAS in 299 NICUs in the US reported that the
percentage of infants who received pharmacotherapy increased from 74% in 2004-2005 to
87% in 2012-2013.13 The same study reported that the most commonly prescribed
medication, morphine, was used in 72% of the infants in 2013, compared to phenobarbital,
methadone and clonidine in 20%, 15% and 9% of the infants, respectively.13
Buprenorphine and dilute tincture of opium (DTO) were only used in less than 1% of the
infants in the same time period.13 Another study that surveyed 235 neonatal units in the
United Kingdom and Ireland in 2008 reported that morphine was the most commonly used
first-line agent in opiate withdrawal (92% of units), followed by phenobarbitone (3.5%),
chloral hydrate (2.5%), methadone (1.5%) and diazepam (0.5%), and that phenobarbitone
was the most commonly used second-line agent (23.7%), followed by chloral hydrate
(15.7%), chlorpromazine (11.6%), morphine (5.5%), benzodiazepine (3.0%) and
methadone (1.5%).25 These findings were in line with the American Academy of Pediatrics
(AAP) Guidelines on NAS, which recommended the use of a drug from the same class as
the drug that caused withdrawal (i.e., opioids) for treatment.2 More recently, the 2012
update of the AAP Guidelines recommended the use of oral morphine solution or
methadone, but the authors also recognized that available evidence on comparative
efficacy from randomized controlled trials in NAS was limited at that time.11

3

1.2.1

Comparison of Pharmacologic Agents

The detailed description and analysis of comparative efficacy studies were
discussed elsewhere. A recent systematic review including 18 randomized clinical trials
of pharmacological therapy (N = 1072) found that sublingual buprenorphine performed
the best in terms of length of treatment, followed by clonidine, DTO, methadone, morphine
and phenobarbital monotherapy, but the analysis results were sensitive to imprecision.26
The authors commented that though prolonged half-life and receptor activity of
buprenorphine might justify shorter lengths of treatment it was associated with, it was
unclear how much such observed benefits of buprenorphine were in fact due to the
optimization of the treatment protocol and weaning schedule in the buprenorphine trials.26
Additionally, the authors noted heterogeneity of criteria for initiation of pharmacotherapy,
dosing changes, addition of adjuvant drugs, and treatment discontinuation among the
included trials.26
On the other hand, safety profiles should also be taken into consideration when
comparing pharmacologic agents. Clinically, the commonly used opioids and clonidine
have favorable safety profiles with inpatient use, while phenobarbital appears clinically
safe though its effect on neurodevelopment is a potential concern.27 Another potential
concern may lie with drug formulation. While preservative-free morphine is commercially
available, the commercially available methadone contains 15% of alcohol, though
preservative-free methadone has been compounded for use in clinical trials.28 On the other
hand, buprenorphine formulation used in neonates for sublingual administration contains
high amount of alcohol.29 It is still unclear what level of ethanol exposure is considered
safe in neonates, but it is recommended that medications containing ethanol should be used

4

with caution in neonates.30 The AAP established an arbitrary ethanol concentration limit
of 0.25 g/L following a single dose.31 However, ethanol concentrations ranging from 0.01
to 1 g/L have been related to CNS adverse effects in children in the literature.32
Another important aspect that needs consideration is the potential effect of
pharmacological agents on the developing brain. As opioid receptors are critical in normal
neurodevelopment, mechanistically opioid exposure is expected to affect neuronal
structure and function.33 Several studies have found that perinatal opioid exposure could
lead to short-term and long-term neurobehavioral consequences.33 At a cellular level,
perinatal opioid exposure has been shown to produce effects ranging from altering
neuronal and µ-receptor density, reducing the content of nerve growth factor, to increasing
vulnerability to neuronal apoptosis.34-37 However, the clinical relevance of these
experimental findings is still unclear, as there are many confounding factors when one
attempts to determine the relationship between perinatal opioid exposure and
neurodevelopmental outcomes in clinical settings. Given the concerns raised by
experimental data, it is recommended that the clinicians should use the lowest effective
dose of opioids for the shortest duration in neonates for sedation and analgesia.38 On the
other hand, α2-adrenergic receptor agonists, dexmedetomidine and clonidine, have been
shown to be neuroprotective in ischemic cerebral injury in preclinical studies, likely due
to their inhibition of extracellular glutamate and aspartate release in ischemia.39-43
Considering the differential effects on neurodevelopment in preclinical studies, it is
worthwhile to further explore the use of α2-adrenergic receptor agonists in NAS and
compare the neurobehavioral outcomes in patients who receive opioids and those who
receive α2-adrenergic agonists as the primary therapy.

5

Last but not the least, as there are variations in starting dose, dose
escalation/weaning schemes and use of adjunctive therapy and nonpharmacological
therapy, results from randomized trials comparing different pharmacologic agents may be
difficult to interpret. Though most treatment protocols involve rapid up-titration of an
opioid and subsequent weaning at typically 10% increments, treatment approaches differ
significantly across institutions, as there is no consensus on the universal standard of
care.44 Therefore, in addition to studying comparative efficacy, optimization of dosing
regimens should also be a priority for future research.

1.3

Factors Associated with Disease Severity in NAS
When interpreting results from studies comparing different treatment agents or

protocols, we must also keep in mind that NAS severity can potentially be affected by
certain clinical factors and genetic factors. Types of opioids that the neonates were exposed
to in utero (e.g., methadone vs. buprenorphine), concomitant prenatal exposure to
substances other than opioids, gestational age, and breastfeeding have all been reported to
be related to NAS severity.5,10 Specifically, it was reported that infants with in utero
exposure to buprenorphine have less severe withdrawal than infants with in utero exposure
to methadone.45-48 Maternal concomitant use of benzodiazepines, antidepressants (e.g.,
selective serotonin reuptake inhibitors [SSRIs]), gabapentin, tobacco and/or illicit
substances has been associated with more severe withdrawal symptoms in neonates.46,47,4955

Additionally, studies have consistently found that term neonates display more severe

abstinence symptoms than preterm neonates.50,56 Some possible explanations include
incomplete neurological development that limits the clinical expression of opioid
withdrawal, slower weaning process due to immature metabolism of opioids, lower total
6

prenatal opioid exposure and decreased placental transfer of opioids in preterm neonates
compared to term neonates.50,52,56,57 Breastfeeding has been consistently associated with
decreased opioid withdrawal severity, potentially due to the act of breastfeeding (e.g., skin
to skin contact) or the effect produced by low quantities of certain opioids passively
transferred by breastfeeding.20,47,58-60 On the other hand, while some studies reported that
males have a tendency to develop more severe withdrawal symptoms, this finding was not
confirmed by others.5,61 The effect of maternal methadone or buprenorphine dose on NAS
severity has been extensively examined, and the majority of the evidence suggested that
the relationship is likely nonsignificant.62-67 In addition to clinical factors, the effect of
genetic disposition has been explored in small studies, which have identified certain
relationships between genetic variants and epigenetic modifications in opioid
receptors/stress response genes and disease severity. The details of these studies are
discussed in Section 3.1. However, it must be noted that these previous genetic studies
suffer from limited sample sizes and/or lack of replication in independent cohorts.14

1.4

Diagnostic Tools in NAS
The optimal assessment tool in NAS has yet to be definitely established, which adds

to the site-to-site variations in treatment strategies and outcomes.10,68 The major
deficiencies of current assessment tools of NAS are their subjectivity and inconvenience
to be administered at bedside.23 The most widely used scoring tool, the original Finnegan
Neonatal Abstinence Scoring Tool, has documented interobserver reliability in initial
clinical studies, but the achievement of high interobserver reliability requires education
and training of hospital personnel.23 Additionally, though preterm neonates and term
infants are known to exhibit differential courses of NAS,52,57 no scoring tools has been
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developed specifically for assessing preterm neonates.23 Efforts have been made to
develop more efficient screening tools, such as the Three-Sign Screening Index and the
Finnegan Neonatal Abstinence Scale – Short Form.69,70 Despite their relative simplicity,
these short assessment tools still suffer from some of the disadvantages of the original
scoring tools. On the other hand, physiologic measures, such as heart rate variability,
pupillary response, measurement of movement, skin conductance were examined as
potential diagnostic parameters of disease severity.71-75 Despite the objective nature of
these measures, none of these physiologic tools is routinely used in clinical settings,68 and
further studies are needed to explore the utility of these measures in guiding treatment.

1.5

Study Objectives
Based on the literature evidence presented above, we could identify several

research gaps in the approaches for treating and managing infants with NAS:
Research Gap 1: There exists significant variability in disease severity and
treatment outcomes, which can be attributed to patient-specific factors (e.g., clinical
factors and genetic disposition) and site-to-site variations in disease management.76-79 The
effect of genetic disposition was explored in small studies, and external validation is still
needed to corroborate the reported association. In addition, previous research has not taken
an integrated approach examining both clinical factors and genetics factors that potentially
affect exposure of treatment agents in NAS neonates using population pharmacokinetic
(PopPK) analysis.
Research Gap 2: Previous retrospective studies showed that use of standard
treatment protocols could reduce treatment and hospitalization duration.80,81 However,
there is a lack of consensus on the optimal NAS treatment protocols on pharmacotherapy
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procedures.82 In-depth understanding of clinical pharmacology for individual agents will
be key to therapy optimization, as it serves as the basis for the use of population
pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation to inform the
design of treatment strategies.
The Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal
Injury to the Young Brain (No-POPPY) study (NCT03396588) at the University of
Kentucky Medical Center is a double-blinded randomized trial aimed to determine
whether treatment of NAS with clonidine will be more effective and result in better early
childhood outcomes than treatment with morphine. Based on data and biospecimen
collected from this trial, our work is intended to pursue the following specific aims:
Specific Aim 1: To investigate the relationship between single nucleotide
polymorphisms (SNPs) in opioid receptors/stress response genes and disease
severity/treatment outcomes in NAS using genetic association analysis.
Specific Aim 2: To investigate the relationship between SNPs that can potentially
affect the PK of morphine/clonidine and the disposition of these two drugs in population
PK analysis (Figure 1.1).
For Specific Aims 1-2, we hypothesize that interpatient variability in treatment
response in NAS can partially be accounted for by genetic factors that affect disease
severity or PK/PD of the pharmacologic agent.
Specific Aim 3. To use population PK modeling and simulation to inform the
optimization of dosing regimen.
We hypothesize that a population PK modeling approach incorporating both
clinical and genetic factors can be used to optimize treatment strategies in NAS.
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Figure 1.1 Potential effect of genetic variants on clonidine and morphine disposition.
Single-nucleotide polymorphisms in proteins (emboldened) are studied in Chapter 4.
1.6

Clinical Study Design
The No-POPPY study is a double-blinded randomized clinical trial. Enrolled

subjects will be designated to 1 of 3 cohorts depending on their exposure during utero,
need for treatment, or lack thereof. Enrollment of subjects started in December 2017 and
is expected to end in March 2022. Target enrollment is 250 infants for cohort 1, 50 infants
for cohort 2, and 30 infants for cohort 3. Of note, cohort 2 was incorporated in the study
protocol since October 2018, and cohort 3 was incorporated since August 2019. Approval
by the Institutional Review Board (IRB) at the University of Kentucky was obtained before
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commencement of the study. Written and informed consent from the parent(s) of the
subject was obtained and documented before subjects’ participation in this trial.
1.6.1

Study Population

Cohort 1 (treated subjects) will include infants exposed to opiates while in utero
and requiring pharmacologic treatment to treat their withdrawal symptoms. Treatment of
these NAS symptoms will use a randomized and double-blind study design to compare the
use of morphine and clonidine.
Cohort 2 (non-treated subjects) will include infants exposed to opiates in utero but
not requiring pharmacologic treatment based on Finnegan scores.
Cohort 3 (control subjects) will include infants not exposed to opiates by maternal
history or negative drug screen and serve as a control group.
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Table 1.1 Inclusion criteria and exclusion criteria for the No-POPPY study
Cohort 1
Cohort 2
Cohort 3
•Gestational age (GA) >35
weeks

•Gestational age (GA) >35
weeks

•Known prenatal opiate
exposure (by mother admitting
use, mom with positive opiate
screen during pregnancy, or
positive neonatal urine and
meconium screening)

•Known prenatal opiate
exposure (by mother admitting
use, mom with positive opiate
screen during pregnancy, or
positive neonatal urine and
meconium screening)

•No known prenatal cocaine
exposure

•No known prenatal cocaine
exposure

•No morphine or clonidine
dose before enrollment

•No morphine or clonidine
dose before enrollment

•Symptomatic with Finnegan
scores (FS): 3 consecutive
scores ≥8, OR 2 consecutive
scores ≥12, and/or with
attending decision to treat for
NAS

•Finnegan scores do not meet
drug treatment criteria

•No seizures

•≤ 7days of age

•No major congenital
malformations

•No blood pressure instability

•≤ 7days of age
•No blood pressure instability
•No major medical condition
in addition to NAS
•Attending physician decides
to start pharmacologic
treatment and agrees to
infant’s study participation

•No seizures
•No major congenital
malformations

•No major medical condition
in addition to NAS
•Attending physician does not
start pharmacologic treatment
and agrees to infant’s study
participation
•Mother must be ≥18 years old
•Parents able to understand
English

•Mother must be ≥18 years old
•Parents able to understand
English
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•Infants not
exposed to opiates
by history and or
urine drug screen
negative
•Gestational age
(GA) >35 weeks
•No major medical
condition
•Mother must be
≥18 years old
•Parents able to
understand English

1.6.2

Research Procedures
1.6.2.1 Pharmacologic treatment

Cohort 1 subjects will be randomized to receive oral morphine or oral clonidine.
Kentucky Children’s Hospital personnel administering the drug will be blinded to the
treatment. Drug will be prepared and dispensed in similarly appearing solutions and
volumes. Newborns requiring a second drug to help relieve the symptoms will be treated
with either the opposite research medication being used and/or phenobarbital for both
groups and at the attending physician’s discretion.
1.6.2.1.1 MORPHINE THERAPY
If a baby is randomized to morphine, the starting dose is 0.06 mg/kg/dose (every 3
or 4 hours, depending on the feeding schedule). Dose will increase by 25% of initial dose
every 12-24 hours until NAS scores are consistently <8 and symptoms are stable – up to
0.12 mg/kg/dose. Once the maximum dose of morphine is reached, add second therapy see “Second Therapy” section. Once the patient is stable, the dose will remain unchanged
(stabilization) for at least 24-48 hours with scores <8. Then weaning may begin by
decreasing the dose by 10% of maximum dose every 24 hours, then continue this wean
pattern, as tolerated. If necessary, the baby may be weaned more frequently at physician’s
discretion. When the dose reaches 0.006 mg/kg/dose and scores are <8 for 24 hours,
change dosing to every 6 hours. If FS <8 for 24-48 hours, may discontinue morphine,
continue to monitor for 48 hours, and then may discharge. If re-escalation is needed, the
last dose level will be administered. If re-escalation is needed, the infant will begin
weaning again on the above weaning schedule once the infant has had scores <8 for 24-48
hours on escalated dose.
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1.6.2.1.2 CLONIDINE THERAPY
Babies randomized to clonidine will receive 1 µg/kg/dose (every 3 or 4 hours,
depending on the feeding schedule). This group will also receive increases by 25% of initial
dose every 12-24 hours until NAS scores are consistently <8 and symptoms are stable – up
to 2 µg/kg/dose. Once the maximum dose of clonidine is reached, add second therapy - see
“Second Therapy” section. The dose will remain unchanged for 24-48 hours once stable
with scores <8. Then, the dose will be decreased by 10% of maximum dose every 24 hours.
If necessary, a baby may be weaned more frequently at physician’s discretion. When the
dose reaches 0.1 µg/kg/dose and scores <8 for 24 hours, change dosing to every 6 hours.
If FS <8 for 24-48 hours, may discontinue clonidine, continue to monitor for 48 hours, and
then the baby may be discharged. If re-escalation is needed the last dose level will be
administered. If re-escalation is needed, the infant will begin weaning again on the above
weaning schedule once the infant has had scores <8 for 24-48 hours on escalated dose.
1.6.2.1.3 SECOND THERAPY
The need for a second drug is defined as failure of the primary research drug. This
can be the secondary research drug and/or phenobarbital, which would be added after
maximum study drug dose failed to control NAS symptoms. The choice of which
secondary therapy to start will be left up to the attending physician (Table 1.2).
1.6.2.2 Biospecimen Collection
Biospecimen collection from each cohort is detailed in Table 1.3. Buccal swabs
collected will be used for SNP genotyping and epigenetic analysis. Blood samples will be
collected in EDTA blood tubes, and the amount of blood collected each time will be
approximately 0.5 mL. For cohort 1 (treated) subjects, up to six blood samples will be
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collected during stay. The first blood sample from treated subjects will be collected before
the start of treatment (baseline blood sample), which will be primarily used for biomarker
analysis. Before buccal swabs were incorporated in the protocol, a small proportion of the
baseline blood sample was also used for SNP genotyping. Except for the baseline blood
sample, all other blood samples collected from treated subjects will mainly be used for PK
analysis. Stool samples collected from treated subjects will be used to study the effect of
opioid exposure on the development and phenotype of the microbiome. The effect of
morphine and clonidine treatment on the microbiome is not part of this work and therefore
its relevance was not presented in the background information.

Table 1.2 Use of second therapy in the No-POPPY study
Adjunct Study Drug
or

Phenobarbital

Dosing based on study protocol

Dosing based on standard of care

BOTH study drugs will remain blinded

Weaning is based on attending
discretion

Weaning based on study protocol and
will be initiated AFTER primary drug
has been discontinued

May be discharged on taper to be
weaned at home

BOTH study drugs must be
discontinued before discharge
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Table 1.3 Biospecimen collection in the No-POPPY study
Biospecimen
Research Cohort 1 Research Cohort 2 Research Cohort 3
Blood draws

Once before
discharge

Once before
discharge

Buccal swabs
Twice before
(incorporated in
discharge
study protocol since
Oct 2018)

Once before
discharge

Once before
discharge

Stool samples
Weekly while on
(incorporated in
treatment
study protocol since
Oct 2018)

-

-

1.7

Up to 6 blood
draws during stay

Thesis Overview
The body of this thesis is organized into three chapters. Chapter 2 describes the

development and evaluation of high-performance liquid chromatography-tandem mass
spectrometry

(HPLC/MS-MS)

methods

that

simultaneously

quantify

plasma

concentrations of morphine, morphine-3-glucuronide (M3G), morphine-6-glucuronide
(M6G) and clonidine. Chapter 3 addresses Specific Aim 1 by evaluating the relationship
between prespecified SNPs and disease severity/treatment outcomes in NAS. Chapter 4
addresses Specific Aims 2 and 3 by investigating the effect of genetic and clinical factors
in population PK analysis of morphine and clonidine and using modeling and simulation
strategies to optimize clonidine dosing regimen.
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CHAPTER 2. DEVELOPMENT AND VALIDATION OF LC/MS-MS METHODS
2.1

Quantification Method on API 2000 LC/MS-MS System
This method has been published as Tang F, Bada H, Ng CM, Leggas M. Validation

of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its
metabolites in human plasma. Biomed Chromatogr. 2019 Jul;33(7):e4527.83 The main
body of the manuscript is included in this section. Following initial experience with the
analysis of clinical samples, it became apparent that concentrations were not quantifiable
in some samples following the lowest doses administered during the weaning phase. We
therefore transferred this method into a more sensitive instrument and performed a partial
validation (see Section 2.2).
2.1.1

Introduction

Neonatal abstinence syndrome (NAS) is a withdrawal syndrome in infants with in
utero exposure to opioids. NAS has become a serious public health issue in recent years,
as its incidence and associated health expenditure have increased significantly in the past
decade.1,12 Pharmacologic therapy is indicated for treating moderate to severe symptoms
in NAS if patients fail to respond to nonpharmacologic therapy. The American Academy
of Pediatrics Guidelines recommended the use of oral morphine and methadone as firstline agents.11 However, the optimal initial drug therapy is still unknown, and there are
ongoing clinical studies that are intended to address this issue.10
Morphine is a μ-opioid agonist for treatment of moderate to severe pain. It is
metabolized extensively through glucuronidation by UDP-glucuronosyltransferase-2B7
(UGT2B7) to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G).84
M6G has been shown to have strong binding affinity for the μ-opioid receptor and have
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significant contribution to analgesia produced by morphine. M3G, on the other hand, has
no analgesic properties due to its low affinity for opioid receptors.85 M3G has been
associated with some neurotoxic symptoms, including hyperalgesia and allodynia.86
The use of clonidine as an adjunctive therapy in NAS has been investigated in
several studies.87,88 Its use as the primary treatment was first reported in several case
series,89-92 followed by a pilot clinical trial that demonstrated shorter treatment duration
with clonidine than with morphine.93 Clonidine is an α2-adrenoceptor agonist commonly
used as an antihypertensive agent.94 In opioid withdrawal, enhanced noradrenergic activity
is observed due to the loss of opiate inhibition on noradrenergic neurons.93 Through
stimulation

of

α2-adrenergic

receptors,

clonidine

decreases

noradrenergic

neurotransmission and thus relieves withdrawal symptoms.93-95
A number of high-performance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS) methods that quantified morphine, M3G and M6G and those that
quantified clonidine in human plasma were reviewed. The lowest limits of quantification
(LLOQ) ranged from 0.25-3.5 ng/mL for morphine, 1-3.5 ng/mL for M3G/M6G,96-98 and
0.01-0.25 ng/mL for clonidine,99-104 and these methods required plasma volumes ranging
from 100 µL up to 1mL. There was one published HPLC-MS/MS method that
simultaneously quantified clonidine, morphine and its two major metabolites that was
highly sensitive and only required 100 µL of plasma.105 However, this method required
the use of an ion-pairing agent as the eluent additive, which could make column-to-column
reproducibility problematic. Additionally, carry-over observed in this method, though
sufficiently removed by extended needle and seal wash programs, was potentially
problematic during method transfer to instruments from different manufacturers. On the
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other hand, compared to the protein precipitation method used in this particular study,
solid-phase extraction (SPE) as the sample preparation method can yield cleaner sample
extracts and more effectively reduce the amount of potential interferences from biological
matrices.
Here, we report the development and validation of a HPLC-MS/MS method to
simultaneously quantify morphine, M3G, M6G and clonidine in human plasma to support
the pharmacokinetic analysis of an ongoing double-blinded randomized clinical trial, the
Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the
Young Brain (No-POPPY) trial (NCT03396588), which compares the use of morphine
versus clonidine in NAS. This assay is accurate, precise and only requires 100 µL of
patient plasma, considering only a limited amount of blood can be drawn from neonates.
These data will be used for future population pharmacokinetic analyses, which aims to
discover sources of variability in drug exposure and response to therapy including
pharmacogenetic covariates identified in genes responsible for metabolism, drug transport
and drug binding receptors.
2.1.2

Materials and Methods
2.1.2.1 Chemicals and Solvents

Reference standards of morphine solution (1.0 mg/mL in methanol), morphine-3β-D-glucuronide solution (100 μg/mL in methanol: water (1:1)), morphine-6-β-Dglucuronide solution (100 μg/mL in methanol: water (1:1)), and clonidine hydrochloride
were purchased from Sigma-Aldrich, Inc (St. Louis, MO, USA). Deuterated internal
standards (IS), clonidine-d4 hydrochloride and morphine-d3 solution (1.0 mg/mL in
methanol) were purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada) and
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Sigma-Aldrich, respectively. HPLC grade methanol (≥99.9%) and LC/MS grade formic
acid (≥99.5%) were obtained from Thermo Fisher Scientific (Waltham, MA, USA).
Ultrapure water was obtained from a Milli-Q water purification system (MilliporeSigma,
Burlington, MA, USA). Pooled blank human plasma obtained from Kentucky Blood
Center was used for method development and validation. Blank human obtained from six
different healthy individuals with potassium EDTA as the anticoagulant was used to assess
selectivity, LLOQ and matrix effect (Innovative Research, Novi, MI, USA).
2.1.2.2 Stock Solutions, Calibrators and Quality Control
Samples
Stock solutions of clonidine hydrochloride and clonidine-d4 hydrochloride were
prepared at 100 μg/mL in methanol. All stock solutions were kept at -20 °C until use.
Working solutions for calibrators and quality control (QC) samples were made on the day
of preparing the standards. Working solutions for calibrators were prepared by diluting
stock solutions with ultrapure water to concentrations of 80, 40, 8, 4, 0.8, 0.4, 0.2 and 0.08
µg/mL for morphine, M3G and M6G; 8, 4, 0.8, 0.4, 0.08, 0.04 and 0.02 µg/mL for
clonidine. Similarly, working solutions for QC samples at three concentrations (low [LQC],
medium [MQC], high [HQC]) were prepared at concentrations of 0.24, 32 and 64 µg/mL
for morphine, M3G and M6G; 0.06, 3.2 and 6.4 µg/mL for clonidine. IS working solution
containing 2.5 μg/mL of morphine-d3 and 250 ng/mL of clonidine-d4 hydrochloride was
prepared freshly on the day of the experiment by diluting stock solutions with ultrapure
water.
Calibrators and QC samples were prepared by spiking 95 μL of blank human
plasma with 5 μL pooled working solutions from four analytes to achieve target
concentrations. For morphine, M3G and M6G, calibrators 1-8 were prepared at 1000, 500,
20

100, 50, 10, 5, 2.5, 1 ng/mL, and QC samples were prepared at 3, 400, and 800 ng/mL. For
clonidine, calibrators 1-7 were prepared at 100, 50, 10, 5, 1, 0.5, 0.25 ng/mL, and QC
samples were prepared at 0.75, 40, and 80 ng/mL. A calibration curve for each analyte was
tested using a zero sample, a blank sample, and nonzero calibrators.
2.1.2.3 Sample Processing
Standards or 100 µL of samples in polypropylene tubes were thawed under room
temperature and centrifuged at 2000 g for 5 to 10 seconds. After centrifugation, 20 μL
freshly prepared IS working solution was added to each tube with the exception of zero
samples, where 20 μL of ultrapure water was added instead. Subsequently, 240 μL of 10
mM ammonium carbonate (pH 10) was added to each tube. All samples were then vortexed
for 5 seconds and centrifuged at 4000 g for 5 min at 4°C.
SPE was performed using Strata-X polymeric reversed phase 30 mg/mL tubes
(Phenomenex, Torrance, CA, USA). Following loading of supernatant to SPE tubes
conditioned with 1 mL methanol and 1 mL 10 mM ammonium carbonate (pH 10), the
tubes were washed with 1 mL of methanol:10 mM ammonium carbonate (5:95 v/v) and
dried under vacuum. Analytes were then eluted with 1 mL acetonitrile:methanol (1:1 v/v).
The sample extracts were evaporated at 40 °C under vacuum and then reconstituted with
50 μL 5% methanol in water with 0.1% formic acid (initial mobile phase). Reconstituted
solutions were thoroughly vortexed for 10 seconds and centrifuged at 2000 g for 5 to 10
seconds. The supernatant was transferred to autosampler glass vials.
2.1.2.4 LC-MS/MS Conditions
LC-MS/MS analyses were conducted with an HPLC system with SIL-20AC
autosampler and LC-20AD pumps (Shimadzu, Tokyo, Japan), coupled with an API 2000
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triple quadrupole mass spectrometer (AB Sciex, MA, USA). A C18 column (Inertsil ODS3, 3 x 100 mm, 4-µm, GL Sciences, Tokyo, Japan) coupled with a guard column (Inertsil
ODS-3, 3 x 10 mm, 4-µm) was used for analyte separation at room temperature. Mobile
phase consisted of 0.1% formic acid in water (phase A) and 0.1% formic acid in methanol
(phase B). Flow rate was 0.2 mL/min, and the injection volume was 10 μL. Temperature
of the autosampler was kept at 15 °C. Mobile phase gradient started with 5% B, which was
increased to 20% over 2 min and then to 40% over 0.5 min. Mobile phase B was held at
40% for 6 min, and then decreased to 5% over 0.5 min, which was held for 6 minutes for
reconditioning. The total run time was 15 min, and the mass spectrum was recorded for
the first 12 min of the run.
The mass spectrometer was equipped with a TurboIonSpray source, and the
measurements were conducted in positive multiple reaction monitoring (MRM) mode. The
following settings were used for the mass spectrometer: turbo heater temperature, 400 °C;
curtain gas, 40 psi; gas 1, 35 psi; gas 2, 50 psi; collision activation dissociation (CAD) gas,
5 psi; ion spray voltage, 5500 V. The predominant ion transitions for each analyte and IS
were selected for quantification, and the ion source parameters for each transition are listed
in Table 2.1. Analyte peaks were quantified using Analyst software (version 1.4.2, AB
Sciex). The analyte to IS peak area ratio was calculated and used for quantification of
analyte concentrations, with morphine-d3 used as the IS for morphine, M3G and M6G, and
clonidine-d4 as the IS for clonidine.
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Table 2.1 MRM transition and ion source parameters for analytes and internal standards
Analyte

Parent
mass
(m/z)

Product
mass
(m/z)

DP
(V)

FP
(V)

EP
(V)

CEP
(V)

CE
(V)

CXP
(V)

Morphine

286.0

165.0

30

395

10

14

56

10

Morphine-d3

289.4

165.0

30

395

10

14

56

10

M3G/M6G

462.0

286.0

63

395

10

22

45

10

Clonidine

230.1

44.3

33

395

10

14

47

27

Clonidine-d4

234.2

48.3

33

395

10

14

47

27

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide; DP: declustering
potential; FP: focusing potential; EP: entrance potential; CEP: collision cell entrance
potential; CE: collision energy; CXP: collision cell exit potential.

2.1.2.5 Method Validation
2.1.2.5.1 LINEARITY, LOWER LIMIT OF QUANTIFICATION (LLOQ) AND LIMIT OF DETECTION
(LOD)
Linearity of analyte response was evaluated by analyzing two full sets of calibrators
on three different days. Regression analysis of the calibration curves with 1/x2 weighting
was performed in RStudio (version 1.1.442, RStudio). A standard on the calibration curve
was accepted as the LLOQ if the analyte response at this concentration was at least five
times the blank response, and the back-calculated concentration had accuracy within 20%
of the nominal concentration and precision ≤20% when expressed as the coefficient of
variation (CV%).106 The LOD was defined as the concentration at which the signal-tonoise ratio was at least 3. The calibration curve was accepted when 75% and a minimum
of six non-zero standards did not deviate by >15% of nominal concentrations (or >20% at
the LLOQ).106 Carryover effect was assessed in blank plasma samples injected after the
highest calibrators and the acceptable limit was below 20% of LLOQ.
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2.1.2.5.2 EXTRACTION RECOVERY
The extraction recovery for each analyte was determined by comparing the peak
area from processed QC samples in triplicates to the peak area from processed blank
samples from six different sources that were spiked post extraction with diluted neat
standards at low, medium and high concentrations. The absolute recovery of IS was
evaluated in a similar manner at concentrations used in sample processing.
2.1.2.5.3 SELECTIVITY AND MATRIX EFFECT
Six different sources of blank plasma from healthy donors were used to test for
interference, selectivity, and matrix effect. Selectivity was determined at the LLOQ, where
the precision should be ≤20% and accuracy within 20% of the nominal concentrations.106
Matrix effect was evaluated by comparing the analyte peak area from processed blank
samples from six different sources that were spiked post extraction with diluted neat
standards at low, medium and high concentrations and analyte peak area from neat
standards diluted in ultrapure water to the corresponding concentrations.
2.1.2.5.4 INTRADAY AND INTERDAY PRECISION AND ACCURACY
Intraday and interday precision and accuracy were assessed by analyzing QC
samples (LQC, MQC, HQC) in five replicates on three different days. Precision at each
concentration was expressed as the CV%, and accuracy at each concentration was back
calculated based on an averaged calibration curve from the method validation process. The
performance of the assay was acceptable if intraday and interday precision was ≤15%, and
the intraday and interday accuracy were within 15% of the nominal concentrations.106
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2.1.2.5.5 STABILITY
Plasma stability of the four analytes were evaluated by analyzing QC samples (N=3
at each concentration) under different storage and handling conditions. Freeze-thawing
stability was tested by subjecting samples to three freeze-thaw cycles prior to processing.
Bench-top stability was evaluated after 24 hours at room temperature, and short-term
stability was determined after 6 days at 4°C. Long-term stability was tested after 1 month
at -80 °C. Autosampler stability was assessed by analyzing processed QC samples 24 hours
after the initial analysis. Stability of clonidine and clonidine-d4 stock solutions was
assessed after 24 hours at room temperature and after 1 month at -20 °C. Stability of
morphine, M3G, M6G and morphine-d3 stock solutions was determined based on
certificates of analysis provided by the manufacturer. The testing samples were considered
stable if back-calculated concentrations based on the averaged calibration curve were
within 15% of the nominal concentrations.
2.1.2.6 Clinical Samples
Blood samples for pharmacokinetic analysis were collected in EDTA tubes from
subjects in the No-POPPY trial. Trial subjects were given oral doses of morphine or
clonidine every 3 or 4 hours based on the feeding schedule. The starting dose was 0.06
mg/kg/dose for morphine and 1 µg/kg/dose for clonidine, and doses were adjusted based
on subjects’ Finnegan scores. Up to three blood samples were collected at random during
treatment and two blood samples within 12 hours after discontinuation of therapy. Plasma
was isolated by centrifugation at 2500 g at 15 min at 4 °C and stored at -80 °C until analysis.
30 plasma samples were analyzed by the aforementioned LC/MS-MS method in a single
run to evaluate its applicability. Based on the US Food and Drug Administration (FDA)
Draft Guidance for Bioanalytical Method Validation,106 three concentrations of QCs in
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duplicate were incorporated in the run, and the run was accepted if at least four out of six
of the QCs concentration results were within 15% of their nominal values, and at least 50%
of QCs at each concentration level were within 15% of their nominal values.
2.1.3

Results and Discussion
2.1.3.1 Method Development

Solid phase extraction was adopted for effective clean-up and enrichment and its
simplicity over liquid-liquid extraction, which was adopted by most of the published
assays for clonidine.101,103,104 Both morphine and clonidine are both weakly basic with
similar pKa values (8.2 and 8.05, respectively).105 Therefore, two types of SPE processing
protocols were compared, one using polymeric reversed phase sorbent (Strata-X,
Phenomenex) with samples buffered with 10 mM ammonium carbonate at pH 10, and the
other using strong cation mixed mode phase sorbent (Strata-X, Drug B, Phenomenex) with
samples buffered with 10 mM ammonium acetate at pH 5. While comparable recovery of
morphine was achieved by the two processing protocols, higher recovery of M3G/M6G
was achieved with Strata-X. Therefore, Strata-X was selected as in the SPE method
development.
Compound-dependent parameters on the mass spectrometer were manually
optimized by directly injecting analytes and IS in 1 μg/mL methanol:water (1:1) solution,
while ion source and gas settings were manually optimized by connecting the syringe
pump and LC system to the source at a flow rate of 0.2 mL/min. For optimization of
chromatography, as M3G and M6G have the same parent ion mass and the same MRM
transition, LC condition was adjusted to achieve good separation of the two analyte peaks.
Initial organic content of the mobile phase was kept low and gradient was kept shallow to
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improve the resolution between structurally similar morphine and its metabolites. Mobile
phase gradient was further adjusted to minimize matrix effect on the late-eluting clonidine
and to optimize separation between endogenous interferences and the analytes. 0.1%
formic acid was added into both the organic and aqueous mobile phases to reduce peak
tailing.
Satisfactory separation of the four analytes was achieved with the optimized LC
condition. The expected retention times for morphine, M3G, M6G and clonidine were 5.5
min, 4.8 min, 6.5 min, and 7.3 min, respectively. The retention times for morphine-d3 and
clonidine-d4 were 5.3 min and 7.3 min.
2.1.3.2 Method Validation
2.1.3.2.1 CALIBRATION CURVES
Calibration curves with eight concentrations prepared in duplicate on three different
days showed good linearity, with R2 from linear regression >0.99 in each run for all
analytes. Average of calibration curves (n = 6) calculated by plotting the analyte/IS peak
area ratio against the nominal concentration and applying 1/x2 weighted linear regression
yielded the following equations: y = 0.000131 + 0.001987x, y = 0.000111 + 0.008071x, y
= 0.000353 + 0.005155x, y = 0.000559 + 0.01479x for morphine, M3G, M6G and
clonidine, respectively. The mean accuracy calculated based on the averaged calibration
curve and precision expressed in CV% were assessed at each calibrator level, and all
standards met the predetermined acceptance criteria except for clonidine at 0.1 ng/mL.
Therefore, the range of reliable response was 1-1000 ng/mL for morphine, M3G and M6G,
and 0.25-100 ng/mL for clonidine. No carryover effect was observed for any of the
analytes.
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2.1.3.2.2 LLOQ AND LOD
The lowest of calibrators were initially chosen based on expected plasma
concentration ranges from the patients in the clinical study. After validation of the
calibration curve, the lowest calibrators, i.e., 0.25 ng/mL for clonidine and 1 ng/mL for
morphine, M3G and M6G were validated as the LLOQ in triplicates in six sources of
plasma. The signal to noise ratio of all analytes at the LLOQ consistently exceeded 5
(Figure 2.1). For morphine, M3G, M6G and clonidine, the mean accuracy was 105.0%,
97.4%, 93.3% and 104.6%, and precision expressed in CV% was 14.3%, 10.2%, 14.1%
and 14.9% at the LLOQ. CV% for analyte/IS area between each source of plasma ranged
between 6.9% and 9.3% Based on a S/N ratio of at least 3, the LOD was estimated to be
0.2 ng/mL, 0.05 ng/mL, 0.2 ng/mL and 0.15 ng/mL for morphine, M3G, M6G and
clonidine, respectively.
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Figure 2.1 Representative chromatograms of morphine at the LLOQ 1 ng/mL (top
panel), morphine-3-glucuronide and morphine-6-glucuronide at the LLOQ 1 ng/mL
(middle panel), and clonidine at the LLOQ 0.25 ng/mL (bottom panel) spiked in human
EDTA plasma.
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2.1.3.2.3 ABSOLUTE RECOVERY
Absolute recovery evaluated at three concentration levels are shown in Table 2.2.
Absolute recovery was relatively consistent across concentrations tested, ranging from
84% to 94% for morphine, 92% to 104% for M3G, 84% to 95% for M6G, and 73% to 88%
for clonidine. The absolute recovery for morphine-d3 and clonidine-d4 was 94% and 88%,
respectively.
Table 2.2 Absolute recovery and matrix effect for each analyte
Recovery (%)
Matrix Effect (%)
Analyte
Low
Medium
High
Low
Medium
High
Morphine

99 ± 4

94 ± 7

96 ± 4

95 ± 16

90 ± 5

97 ± 5

M3G

90 ± 11

91 ± 8

98 ± 4

104 ± 6

101 ± 6

106 ± 3

M6G

98 ± 16

87 ± 9

101 ± 4

92 ± 13

97 ± 4

94 ± 4

Clonidine

79 ± 14

88 ± 6

93 ± 4

93 ± 5

85 ± 3

94 ± 9

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide. Results are
presented as mean ± standard deviation.
2.1.3.2.4 SELECTIVITY AND MATRIX EFFECT
As shown in Table 2.2, the observed matrix effect was close to 100% at tested
concentrations for morphine, M3G and M6G. There was potentially a small matrix effect
on clonidine. However, as a stable isotope labeled internal standard was used for clonidine,
matrix effect would have been compensated during analytical runs. The selectivity of the
method was confirmed from the absence of interfering peaks in blank plasma (pooled
plasma and six sources of single donor plasma) within the retention time window of the
analytes and IS (Figure 2.2).
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Figure 2.2 Representative chromatogram of blank human EDTA single donor plasma in
the MRM mode at five ion transitions (m/z 286.0 → 165.0, 289.4 → 165.0, 462.0 →
286.0, 230.1 → 44.3, and 234.2 → 48.3). Arrows represent expected retention times for
analytes and internal standards (in the order of morphine-3-glucuronide, morphine and
morphine-d3, morphine-6-glucuronide, clonidine and clonidine-d4).
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2.1.3.2.5 INTRADAY AND INTERDAY PRECISION AND ACCURACY
Precision and accuracy data of the QC samples are presented in Table 2.3. The
method showed intraday and interday CV% ≤15% for all analytes. Intraday and interday
accuracy in the range of 95.4%-99.2% and 93.3%-97.1% for morphine, 90.4%-110.3%
and 92.7%-111.3% for M3G, 97.3%-103.4% and 90.6%-100.8% for M6G, 102.5%-105.4%
and 101.0%-108.9% for clonidine. The predetermined criteria of precision and accuracy
were therefore achieved by this assay.
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Table 2.3 Precision and accuracy of QC samples
Analyte

Morphine

M3G
Intraday
(N=5)
M6G

Clonidine

Morphine

M3G
Interday
(N=15)
M6G

Clonidine

Nominal
Concentration
(ng/mL)

Mean ± SD

Precision
(%)

Accuracy
(%)

3

2.97 ± 0.39

15

99.2

400

382 ± 8.5

2.3

95.4

800

786 ± 17

2.1

98.2

3

2.71 ± 0.15

5.9

90.4

400

437 ± 33

7.5

109

800

883 ± 23

2.6

110

3

2.92 ± 0.24

10

97.3

400

414 ± 35

8.5

103

800

818 ± 33

4.1

102

0.75

0.77 ± 0.07

13

103

40

41.0 ± 0.99

2.5

103

80

84.3 ± 3.1

3.8

105

3

2.80 ± 0.34

14

93.3

400

374 ± 13

3.4

93.4

800

777 ± 16

2.1

97.1

3

2.78 ± 0.29

11

92.7

400

424 ± 34

8.0

106

800

890 ± 50

5.7

111

3

2.72 ± 0.35

15

90.6

400

403 ± 48

12

101

800

790 ± 78

9.9

98.7

0.75

0.82 ± 0.05

10

109

40

40.4 ± 1.6

4.0

101

80

82.0 ± 4.0

4.9

103

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide.
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2.1.3.2.6 STABILITY
Based on the acceptance criteria of accuracy ≤15%, all analytes were stable in
plasma after three freeze-thawing cycles. They were also stable in plasma for at least 24
hours at room temperature, 6 days at 4 °C, and for 1 month at -80 °C. Analytes in processed
samples were stable in the autosampler for at least 24 hours (Table 2.4). Clonidine and
clonidine-d4 stock were shown to be stable for at least 24 hours at room temperature (91.3%
and 106.9% of baseline) and 1 month at -20 °C (94.3% and 103.8% of baseline).
Table 2.4 Stability of analytes in various conditions
Analyte

Morphine

M3G

M6G

Clonidine

Accuracy (%)

Nominal
Concentration
(ng/mL)

24 h in
autosampler

24 h at room
temperature

6 days at 4
°C

1 month at
-80 °C

Freezethawing

3

110.9

113.7

115.0

93.0

91.5

400

95.7

105.4

105.3

95.4

99.2

800

100.3

103.4

110.1

96.4

102.6

3

100.0

98.3

93.0.1

104.1

103.5

400

107.8

106.0

101.2

101.8

110.1

800

112.2

113.0

113.0

99.7

110.5

3

101.4

112.8

109.8

95.7

102.1

400

102.4

111.8

107.9

95.8

107.0

800

101.5

106.1

111.0

87.6

97.1

0.75

95.8

98.5

97.8

101.7

110.2

40

102.5

98.5

97.5

107.0

98.5

80

105.4

96.8

99.2

111.5

102.2

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide.
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2.1.3.3 Application on Clinical Samples
Prior to each analysis, QC samples were analyzed to ensure that the system
suitability criteria were met. Among the 30 plasma samples analyzed, 15 samples were
collected from the morphine group and the remaining from the clonidine group. Among
plasma samples collected from the clonidine group, 12 samples had concentrations ranging
from 0.25 to 2.2 ng/mL (Figure 2.3A), while 3 samples (collected from the same subject)
were below the LLOQ. The observed concentrations agreed with reported values in a
previous pharmacokinetic study in newborns with NAS,107 and they corresponded to or
exceeded concentrations that were found to achieve sedation in pediatric patients (0.3-0.8
ng/mL).108
Plasma samples collected from the morphine group during treatment (N=9) had
morphine concentrations ranging from 1.3 to 32 ng/mL, M3G concentrations from 38 to
176 ng/mL, and M6G concentrations from 5.6 ng/mL to 36 ng/mL (Figure 2.3B). For the
samples collected within 12 hours after drug discontinuation, morphine concentrations
were mostly below 1 ng/mL, while M3G concentrations ranged from 1.1 to 16 ng/mL and
M6G concentrations from <1 ng/mL to 4.2 ng/mL. The concentration range of morphine
was similar to levels that were found to provide effective analgesia in postoperative
neonates (between 15.4 and 22 ng/mL).109 Furthermore, the range of M3G/M6G
concentration ratio (between 0.16 and 0.26) corresponded well to reported values in
neonates (between 0.05 and 0.22).109,110 Representative chromatograms from study
subjects are shown in Figure 2.4.
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Figure 2.3 Concentrations of analytes measured in A) plasma samples above the lower
limit of quantification from infants that received clonidine treatment and B) plasma
samples collected during treatment from infants who were treated with morphine.
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Figure 2.4 Example chromatograms from patient samples in the morphine group (upper
panel) and the clonidine group (lower panel). Patient sample numbers are hidden from the
figure legend to maintain blinding of the clinical trial.

37

2.1.4

Conclusions

In this study, an accurate, precise and selective LC/MS-MS assay was developed
and validated to quantify plasma concentrations of morphine, M3G, M6G and clonidine.
This method was able to separate structurally similar glucuronide metabolites of morphine
and minimize interference from endogenous compounds in plasma. Consistent and
satisfactory recovery rates were achieved for all analytes, and the assay only requires a
starting plasma volume of 100 µL. The method was successfully applied to clinical trial
samples. The assay has LLOQ of 1 ng/mL for morphine, M3G and M6G, and 0.25 ng/mL
for clonidine. While the LLOQ of morphine, M3G and M6G were comparable to or lower
than those in published methods, the LLOQ of clonidine was at the upper end of the
reported range. Future work will be dedicated to lowering the LLOQ of clonidine by
transferring the current method to a more sensitive mass spectrometry and performing
necessary steps of partial validation for additional sensitivity needed for pediatric
pharmacokinetic analysis.

2.2

Quantification Method on AB SCIEX QTRAP 6500+ LC/MS-MS System
The quantification method detailed in Section 2.1 was transferred to AB SCIEX

QTRAP 6500+ LC/MS-MS system to lower the LLOQ of clonidine and reduce the volume
of plasma needed for each run. Partial validation of the new method and cross-validation
with the previous method were completed.

2.2.1

Materials and Methods
2.2.1.1 Chemicals and Solvents
38

Reference standards of morphine solution (1.0 mg/mL in methanol), morphine-3β-D-glucuronide solution (100 μg/mL in methanol:water (1:1)) and morphine-6-β-Dglucuronide solution (100 μg/mL in methanol:water (1:1)) were purchased from SigmaAldrich, Inc (St. Louis, MO, USA). Reference standard of clonidine hydrochloride was
obtained from Cayman Chemical Company (Ann Arbor, MI, USA). Deuterated internal
standards of morphine-d3 solution (1.0 mg/mL in methanol), morphine-d3-3-β-Dglucuronide solution (100 µg/mL in methanol with 0.05% NaOH) and morphine-6-β-Dglucuronide-d3 solution (100 µg/mL in methanol:water (1:1)) were obtained from SigmaAldrich, and clonidine-d4 hydrochloride was purchased from CDN Isotopes (Pointe-Claire,
Quebec, Canada). Other chemicals and materials were identical to those described in
Section 2.1.2.1.
2.2.1.2 Stock Solutions, Calibrators and Quality Control
Samples
Stock solutions of clonidine hydrochloride and clonidine-d4 hydrochloride were
prepared at 100 μg/mL in methanol. All stock solutions were kept at -20 °C until use.
Working solutions for calibrators and QC samples were made on the day of preparing the
standards. Working solutions for calibrators were prepared by diluting stock solutions with
ultrapure water to concentrations of 40, 20, 4, 2, 0.4, 0.2, 0.1 and 0.04 µg/mL for morphine,
M3G and M6G; 4, 2, 0.4, 0.2, 0.04, 0.02, 0.01 and 0.004 µg/mL for clonidine. Similarly,
working solutions for LQC, MQC and HQC were prepared at concentrations of 0.12, 16
and 32 µg/mL for morphine, M3G and M6G; 0.012, 1.6 and 3.2 µg/mL for clonidine. IS
working solution containing 1.25 μg/mL of morphine-d3, 0.25 μg/mL morphine-d3-3-β-Dglucuronide , 0.25 μg/mL morphine-6-β-D-glucuronide-d3 solution, and 125 ng/mL of
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clonidine-d4 hydrochloride was prepared freshly on the day of the experiment by diluting
stock solutions with ultrapure water.
Calibrators and QC samples were prepared by spiking 45 μL of blank human
plasma with 5 μL pooled working solutions from four analytes to achieve target
concentrations. For morphine, M3G and M6G, calibrators 1-8 were prepared at 1000, 500,
100, 50, 10, 5, 2.5, 1 ng/mL, and QC samples were prepared at 3, 400, and 800 ng/mL. For
clonidine, calibrators 1-8 were prepared at 100, 50, 10, 5, 1, 0.5, 0.25, 0.1 ng/mL, and QC
samples were prepared at 0.3, 40, and 80 ng/mL. A calibration curve for each analyte was
tested using a zero sample, a blank sample, and eight nonzero calibrators.
2.2.1.3 Sample Processing
Standards or 50 µL of plasma samples in polypropylene tubes were thawed under
room temperature and centrifuged at 2000 g for 5 to 10 seconds. After centrifugation, 20
μL freshly prepared IS working solution was added to each tube with the exception of zero
samples, where 20 μL of ultrapure water was added instead. Subsequently, 700 mL cold
methanol:acetonitrile 1:1 with 0.1% formic acid (kept on dry ice) was added to all tubes.
All samples were then vortex for 10 seconds and incubated at -20 °C for 20 min, followed
by centrifugation at 20000 g for 20 min at 4°C. Supernatant was transferred to new tubes.
Sample extracts were evaporated at 40-45 °C under vacuum and reconstituted with 50 μL
ultrapure water. Reconstituted solutions were thoroughly vortexed for 10 seconds and
centrifuged at 20000 g for 20 min at 4 °C. The supernatant was transferred to autosampler
glass vials.
2.2.1.4 LC-MS/MS Conditions
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LC-MS/MS analyses were performed on QTRAP 6500+ LC-MS/MS system (AB
Sciex, MA, USA). Mobile phases and the column used were the same as described in
Section 2.1.2.4. Flow rate was 0.2 mL/min, and the injection volume was 5 μL.
Temperature of the autosampler was kept at 15 °C, and temperature of the column oven
was kept at 20 °C. Mobile phase gradient was slightly modified from Section 2.1.2.4:
Mobile phase started with 5% B. B composition was increased to 20% over 2 min and then
to 40% at 3 min. Mobile phase B was held at 40% until 8.9 min, decreased to 5% at 9 min,
and held at 5% for additional 6 minutes for reconditioning. The total run time was 15 min.
Needle rinsing using methanol:isopropanol 1:1 with a volume of 1000 µL was added
before and after sample injection was included to minimize carryover.
The following settings were used for the mass spectrometer: heater temperature,
350 °C; curtain gas, 35 psi; gas 1, 90 psi; gas 2, 60 psi; CAD gas, 10 psi; ion spray voltage,
4000 V. Measurements were performed in positive MRM mode, and the ion transitions
monitored for each analyte and IS were listed in Table 2.5. Analyte peaks were quantified
using MultiQuant software (version 3.0.3, Sciex). The area ratio of analyte to its
corresponding deuterated isotope was calculated and used for quantifying analyte
concentrations.
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Table 2.5 MRM transitions and ion source parameters for analytes and internal standards
Analyte

Parent
mass
(m/z)

Product
mass
(m/z)

DP (V)

EP (V)

CE (V)

CXP (V)

Morphine

285.9

165.3

100

10

51

6

Morphine-d3

289.1

165.3

100

10

51

6

M3G/M6G

462.1

286.2

94

7

45

16

M3G-d3
/M6G-d3

465.1

289.2

81

7

45

16

Clonidine

230.0

213.2

80

10

35

7

Clonidine-d4

234.0

217.2

80

10

35

7

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide; DP: declustering
potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential.
2.2.1.5 Method Validation
5 replicates of QC samples (LQC, MQC, HQC) and LLOQ samples were run on
three different days to test the intraday and interday precision and accuracy. Precision
expressed as CV% was acceptable if it was within 15% at each QC level and within 20%
at the LLOQ. Accuracy was acceptable if within 15% of nominal concentrations at each
QC level and within 20% of the nominal at the LLOQ. Extraction recovery and matrix
effect were evaluated using three replicates of QCs at three levels. Selectivity was
evaluated using six sources of single donor plasma. Long-term plasma stability at -80 °C
was tested using 3 sets of QC samples stored for 10 months.
2.2.1.6 Cross-validation with Previous Method
Cross-validation was performed using the same sets of QC samples evaluated in
long-term plasma stability. These samples were analyzed and quantified with both
methods. The two methods were cross-validated if accuracy at each concentration level
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was between 85% and 115% of the nominal concentration, and precision expressed as CV%
was within 15%.
2.2.1.7 Clinical Samples
Trial design and blood sample collection process were as described in Section
2.1.2.6. In each sample run, two sets of QCs (at three levels) and one set of calibrators
were incorporated. The run was accepted if at least four out of six of the measured QCs
concentrations were within 15% of their nominal values, and at least 50% of QCs at each
level were within 15% of their nominal values.
2.2.2

Results and Discussion

2.2.2.1 Method Development and Validation
As the original method from API 2000 was transferred to an instrument with much
higher sensitivity, we were able to simplify the sample processing procedure from SPE to
protein precipitation and reduce the plasma volume needed from 100 µL to 50 µL.
Additionally, the LLOQ of the clonidine was decreased from 0.25 ng/mL to 0.1 ng/mL.
However, further lowering of the LLOQ was limited by the blank response seen in human
plasma. In this method, deuterated IS was used for every analyte, which added to the
robustness of the method.
Precision and accuracy data of QCs and LLOQ samples are shown in Table 2.6.
The method passed the predetermined accuracy and precision criteria. Compared with the
previous method, range of reliable response remained the same for morphine/M3G/M6G
at 1-1000 ng/mL, and it was extended to 0.1-100 ng/mL for clonidine.
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Table 2.6 Precision and accuracy of QCs and LLOQ samples
Intraday (N=5)
Analyte

Morphine

M3G

M6G

Clonidine

Interday (N=15)

Nominal
Concentration
(ng/mL)

Precision
(%)

Accuracy
(%)

Precision
(%)

Accuracy
(%)

1

1.8

96.7

3.7

97.7

3

2.2

103.6

4.0

103.5

400

1.3

98.3

2.0

100.1

800

1.7

96.3

1.9

97.8

1

3.2

106.0

3.6

103.0

3

1.3

106.8

2.3

104.7

400

0.6

100.2

1.3

99.2

800

1.3

95.3

2.3

94.6

1

3.9

93.9

3.9

93.2

3

3.5

101.6

2.9

100.1

400

1.2

95.7

1.6

95.5

800

1.8

98.9

2.7

96.9

0.1

12.3

83.8

16.9

88.2

0.3

5.1

113.3

4.0

112.2

40

1.3

98.2

1.2

98.0

80

1.8

90.0

1.7

89.5

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide
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Absolute recovery and matrix effect at three concentrations are shown in Table 2.7.
Absolute recovery was relatively consistent across three concentrations. Except for
clonidine, significant matrix effect was observed for morphine, M3G and M6G. However,
since deuterated labeled internal standards were used for every analyte, matrix effect could
be completely accounted for during runs. In six sources of plasma, the blank response of
analytes within the respective retention time window was < 1/5 LLOQ, and relative blank
response compared to IS was negligible.
Table 2.7 Absolute recovery and matrix effect
Recovery (%)
Analyte
Low
Medium
High

Matrix Effect (%)
Low

Medium

High

Morphine

109

129

92

37

36

35

M3G

106

119

84

54

48

54

M6G

93

94

78

12

14

15

Clonidine

102

93

92

94

85

85

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide
Results from long-term stability experiments are presented in Table 2.8. Based on
the mean accuracy of QC samples, all four analytes were stable in plasma for at least 10
months at -80 °C. Cross-validation results are shown in the same table. Measurements of
the same three sets of QC samples passed accuracy and precision criteria with both
methods. Therefore, the two LC/MS methods were considered cross-validated.
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Table 2.8 Long-term stability and cross-validation results
Method on QTRAP 6500+

(also 10-month -80 °C stability)

Analyte

Morphine

M3G

M6G

Clonidine

Method on API 2000

Nominal
Concentration
(ng/mL)

Accuracy (%)

Precision
(%)

Accuracy
(%)

Precision
(%)

3
400
800
3
400
800
3
400
800
0.3
40
80

89
100
97
103
101
99
101
104
101
89
94
85

1.1
1.8
0.9
0.6
0.8
0.5
2.4
3.4
0.8
3.2
2.1
0.2

109
111
115
93
99
105
92
89
98
93
102
98

6.1
0.7
1.8
13.9
2.6
0.4
14.8
3.4
6.1
9.9
5.1
3.4

M3G: morphine-3-β-glucuronide; M6G: morphine-6-β-glucuronide
2.2.2.2 Clinical Samples
The validated LC/MS method was successfully used to quantify analyte
concentrations in patient plasma samples collected from the No-POPPY trial. Of note,
samples tested to have clonidine levels that were lower than the LLOQ on API 2000 were
retested using the new method on QTRAP 6500+.
2.2.3

Conclusion

A LC/MS-MS method that simultaneously quantifies morphine, M3G, M6G and
clonidine was partially validated and cross-validated with the previously published method
by our group. This method has been successfully used to quantify analyte concentrations
in clinical samples and will continue to be used to support PK analysis.
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CHAPTER 3. GENETIC ASSOCIATION ANALYSIS
3.1

Introduction
Small studies have investigated the relationship between several SNPs in opioid

receptors or stress response genes and NAS outcomes (e.g., length of hospitalization, need
for pharmacologic treatment).14
The µ-opioid receptor gene OPRM1 has been extensively investigated in adult
opioid addiction. The G allele in rs1799971 (118A>G) has been associated with the
vulnerability to develop opioid dependence in adults, but the findings were conflicting.111
The association between this particular SNP and NAS severity has been investigated in
two studies. One study including 86 opioid-exposed mother-infant dyads reported
significantly shorter length of hospitalization and lower risk for needing pharmacologic
treatment in those carrying at least one copy of the G allele,112 while another study of 21
neonates by Mactier et al. found no association between the G allele and need for
pharmacologic treatment.113 In addition to the OPRM1 gene, potential relationship
between SNPs in 𝛿𝛿-opioid and 𝜅𝜅-opioid receptor genes (OPRD1 and OPRK1) and NAS
severity was investigated in one study, in which 8 SNPs in OPRD1 and 5 SNPs in OPRK1
were tested in 86 mother-infant dyads.114 The authors reported associations between two
SNPs and worse NAS severity: the OPRK1 rs702764 C allele in the infants and the OPRD1
rs204076 A allele in the mothers.114
The PNOC gene encodes prepronociceptin, which is a precursor to the opioid-like
neuropeptide, nociceptin. In two studies by Wachman et al., one with 86 and another with
113 mother-infant dyads, the PNOC rs351776 A allele and the rs4732636 A allele were
associated with higher risk of needing two medications for NAS treatment, but the
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association between rs2614095 A allele with the length of hospitalization was
inconsistent.114,115
Investigation on SNPs in the COMT gene encoding the catechol-Omethyltransferase, an enzyme involved in the metabolism of dopamine, revealed that two
SNPs, rs4680 (472 G>A) G allele and rs740603 A allele, were related to shorter length of
stay in one cohort (n=86);112,114 however, this finding was not replicated in a separate
cohort (n = 113) or in the two cohorts combined (n = 199).115 In addition, the study by
Mactier et al. did not find an relationship between rs4680 and need for treatment.113
Epigenetic modification in the form of methylation in particular cytosine:guanine
(CpG) sites in the OPRM1 promoter region in opioid-exposed neonates and their mothers
has been studied by Wachman et al. in two studies, one with 86 infants and another with
68 mother-infant dyads.116,117 Prior studies have associated chronic opioid exposure in
adults to increased methylation at certain CpG sites in the promoter region of OPRM1,
leading to its reduced gene expression.118,119 The two studies by Wachman et al. found that
hypermethylation at several CpG sites in the OPRM1 promoter region in NAS infants or
in the mothers was related to increased need for pharmacologic treatment/adjunctive
pharmacologic treatment or increased infant length of stay, respectively.116,117 However,
the CpG site associations identified in these two studies were not in agreement.116,117 As
current understanding maintains that epigenetic changes induced by environmental factors
are rarely transgenerationally inherited,120 observed epigenetic modifications in these
neonates likely occur as a response to in utero exposure to opioids.
This chapter will be organized into methods, results and discussions on the
association analysis of specific infant genetic variants (SNPs) with NAS outcomes.
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Previous studies suffered from the problem of limited sample size and sometimes
conflicting results on the same SNP. Therefore, the first goal of our genetic association
analysis was to investigate whether there was potential association between two previously
studied SNPs (OPRM1 rs1799971 and COMT rs4680) and NAS severity. Given that half
the subjects in the NO-POPPY trial were randomized to receive clonidine, the second goal
of the genetic association analysis was to investigate whether genetic variants in
downstream targets of clonidine were related to treatment response to clonidine in NAS.
Clonidine is a α2-adrenergic receptor agonist that couples with G-protein. The rs5443
(825C>T) polymorphism of the G-protein beta 3 subunit (GNB3) gene has been shown to
be associated with signs of sympathetic activity.121 T allele carriers have shown increased
signal transduction due to stimulation of the α2-adrenergic receptor in vitro.122 Clinically,
T allele carriers have demonstrated increased antihypertensive response in healthy
volunteers, increased gastrointestinal response in patients with irritable bowel disease
(IBS), and increased diuretic response in patients with cirrhosis with refractory ascites in
response to clonidine treatment.122-124 The rs1800544 (-1291G>C) polymorphism in
ADRA2A (alpha 2A-adrenergic receptor) has been studied in patients with IBS who
received clonidine, where G allele carriers demonstrated better post-clonidine
gastrointestinal functions.123 Therefore, the second goal of this genetic association analysis
was to explore whether the rs5443 polymorphism in GNB3 and rs1800544 polymorphism
in ADRA2A were related to treatment response in NAS patients receiving clonidine.
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3.2

Materials and Methods
3.2.1

Subjects, Sample Collection and Sample Processing

The study population in this analysis included all pharmacologically treated (cohort
1) and non-treated (cohort 2) subjects enrolled in the No-POPPY trial (NCT03396588)
from the start of trial (December 2017) up to February 2020. The details of this clinical
trial are mentioned in Section 1.6. For SNP genotyping, whole blood samples collected in
EDTA blood tubes (for first 30 treated subjects enrolled in the trial) or buccal swab
samples (for subjects enrolled later in the trial) collected by ORAcollect for Pediatrics
(OC-175) collection kits (DNA Genotek, Ottawa, Ontario) were used. Whole blood
samples were refrigerated before DNA extraction, where 5µL of whole blood was lysed
by the DNA Extract All Reagents Kit following the manufacturer’s instructions for
TaqMan Sample-to-SNP Kit (Thermo Fisher Scientific, Waltham, MA). The sample
lysates were then stored at -80 °C until analysis. Buccal swab samples collected in OC175 were stored at room temperature before DNA extraction. Genomic DNA from buccal
swabs was purified by the prepIT•L2P reagent following the manufacturer’s instructions
(DNA Genotek). Purified genomic DNA was quantified using a NanoDrop
spectrophotometer (Thermo Fisher Scientific), diluted to 5 ng/µL in TE buffer and stored
at -20 °C until use.
3.2.2

Real-time PCR based SNP Genotyping

DNA samples were genotyped for the following SNPs: OPRM1 rs1799971 (assay
C___8950074_1_), COMT rs4680 (assay C__25746809_50), GNB3 rs5443 (assay
C___2184734_10) and ADRA2A rs1800544 (assay C___7611979_10) using commercially
available TaqMan SNP Genotyping Assays on QuantStudio 7 Flex Real-Time PCR
System (Thermo Fisher Scientific). Each PCR reaction mix was set up according to the
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manufacturer’s instructions for wet DNA method, consisting of TaqPath ProAmp Master
Mix, TaqMan Genotyping Master Mix, nuclease-free water and DNA sample (blood lysate
or diluted purified DNA from buccal swab), to a total reaction volume of 10 µL or 20 µL
in 384-well plates. For 10 µL reactions, each reaction mix consisted of 5 µL 2X TaqPath
ProAmp Master Mix, 0.5 µL 20X TaqMan Genotyping Master Mix, 2.5 µL nuclease-free
water, and 2 µL DNA sample; for 20 µL reactions, each reaction mix consisted of 10 µL
2X TaqPath ProAmp Master Mix, 1 µL 20X TaqMan Genotyping Master Mix, 5 µL
nuclease-free water, and 4 µL DNA sample. According to the manufacturer’s instruction,
thermal cycling condition for assay C__25746809_50 (a TaqMan Drug Metabolism
Enzyme genotyping assay) was 10 minutes of holding at 95 °C followed by 50 cycles of
15 seconds at 95 °C and 90 seconds at 60 °C. The thermal cycling condition for the other
three assays (TaqMan Predesigned SNP genotyping assays) was 10 minutes of holding at
95 °C followed by 40 cycles of 15 seconds at 95 °C and 60 seconds at 60 °C. Genotyping
results were analyzed using TaqMan Genotyper Software (ver. 1.4.0, Thermo Fisher
Scientific) based on allelic discrimination plots and exported for statistical analysis.
3.2.3

Statistical Analysis

Observed allele frequencies were compared with frequencies reported in the CEU
population (Northern Europeans from Utah) in the 1000 Genomes Project
(https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) using the χ2 test at α = 0.05.
For analysis on OPRM1 rs1799971 and COMT rs4680 polymorphisms, the
following outcome measures were used for all included trial patients (treated and nontreated): length of stay (LOS), treatment days on study drug, need for pharmacologic
treatment, need for adjunctive pharmacologic treatment and need for dose escalation to
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achieve symptom stabilization. For analysis on GNB3 rs5443 and ADRA2A rs1800544
polymorphisms, the following outcome measures were used for treated subjects receiving
clonidine: LOS, treatment days on clonidine, need for adjunctive pharmacologic treatment
and need for dose escalation to achieve symptom stabilization.
Before evaluating the association between prespecified SNPs and outcome
measures, the effect of the following clinical variables on outcome measures was first
evaluated in univariate linear or logistic regression at α = 0.05: gender of the infant,
preterm birth (gestational age<38weeks), breastfeeding, type of maternal medication
assisted treatment (MAT, buprenorphine vs. methadone), maternal use of tobacco,
benzodiazepines, SSRIs, gabapentin and barbiturates during pregnancy. Statistically
significant factors were then considered in multivariate analysis. For the analyses on the
relationship between each SNP and outcome measures, both dominant and recessive
genetic models were tested first in unadjusted analysis and subsequently in adjusted
analysis, if indicated. For measures that were continuous, unpaired t-test (assuming equal
or unequal variance as determined by F test) and multivariate linear regression, if indicated,
were conducted for each SNP. For measures that were categorical, Fisher’s exact test and
multivariate logistic regression, if indicated, were conducted for each SNP. Point-wise
significance for SNP associations was set at a level of 0.05. To adjust for multiple
comparisons, a Bonferroni corrected significance level of 0.0125 was used for experimentwise significance. All statistical analyses were performed in R (ver. 3.6.2, The R
Foundation for Statistical Computing, Austria) under R Studio environment (ver.
1.2.5019).
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3.3

Results
3.3.1

Demographics

A total of 107 subjects (89 treated and 18 non-treated) were consented and enrolled
in the No-POPPY study since trial initiation (December 2017) up to February 2020. Of the
107 subjects, 3 subjects were reverse transferred to other hospitals and 5 withdrew their
consent from the study. Therefore, 99 trial subjects (81 treated and 18 non-treated) were
included in the analysis on OPRM1 rs1799971 and COMT rs4680. The demographics of
these subjects are summarized in Table 3.1. The majority of the trial subjects were
Caucasian, with a mean gestational age of 269 days. Among the mothers, 69% and 8%
were on buprenorphine- and methadone-maintenance therapy during pregnancy,
respectively. Additionally, 81% of the mothers reported use of tobacco during pregnancy.
Maternal concurrent use of other substances (benzodiazepines, SSRIs, gabapentin and
barbiturates) ranged from 3% to 13%. Of the 81 treated subjects, 39 clonidine-treated
subjects were included in the analysis on GNB3 rs5443 and ADRA2A rs1800544 (Table
3.1). There were no notable differences in the demographics between the total trial cohort
and the clonidine-treated cohort.

3.3.2

Association Between Potential Covariates and Severity

As shown in Table 3.2, the trial subjects had a mean LOS of 19.7 days and mean
length of primary treatment (i.e., the study drug) of 14.2 days. The average LOS of our
trial subjects was slightly shorter than the average of 22.3 days reported in the previous
genetic study by Wachman et al., which reported associations between COMT
rs4680/OPRM1 rs1799971 and NAS severity.112 In our trial, 82% of the subjects needed
pharmacologic treatment. This proportion was higher than the 65% reported by Wachman
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et al.112 However, this number (82%) was supposedly higher than the actual proportion of
NAS patients who need pharmacologic treatment seen by our trial site, as the initial study
protocol only allowed recruitment of treated subjects, and non-treated subjects were added
later to the trial in protocol amendment. Among the clonidine-treated subjects, 38%
required adjunctive pharmacologic treatment, while 82% required dose escalation of
clonidine treatment. Both indices indicated there was much room for improvement in the
current clonidine dosing regimen, and the implications of which will be discussed more in
detail in Chapter 4.
Results on the association between potential covariates and outcomes measures are
summarized in Tables 3.3 – 3.5. In contrast to the study by Wachman et al., in our treated
cohort breastfeeding was not found to be a significant covariate on LOS.112 In fact, only
maternal gabapentin use during pregnancy was found to be associated with longer LOS
and length of treatment on the study drug (Table 3.3). On average babies born to mothers
with positive history of gabapentin use during pregnancy stayed in hospital for 9.7 more
days and on study drug for 6.8 more days compared those born to mothers without
gabapentin use (p<0.05). As shown in Table 3.4, none of the tested covariates showed
significant effect on the need for pharmacologic treatment. When the need for adjunctive
pharmacologic treatment was tested as an endpoint, breastfeeding (some or exclusive) was
significantly related to decreased need for adjunctive treatment, while maternal use of
benzodiazepines or SSRIs during pregnancy was significantly associated with increased
need for adjunctive treatment. Preterm birth, on the other hand, was related to a trend
toward a decreased risk of needing adjunctive treatment. As shown in Table 3.5, none of
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the tested covariates had a significant association with the need for dose escalation of the
study drug.
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Table 3.1 Demographics of trial subjects (n=99) and clonidine-treated subjects (n=39)
Trial subjects

Clonidine-treated subjects

Demographics

N (%)

N (%)

Preterm (GA<38 weeks)

32 (32%)

11 (28%)

Infant sex, male

56 (57%)

24 (62%)

84 (85%)

33 (85%)

1 (1%)

1 (3%)

Multiple

11 (11%)

4 (10%)

Unknown

3 (3%)

1 (3%)

None

19 (19%)

6 (15%)

Buprenorphine

68 (69%)

27 (69%)

Methadone

8 (8%)

4 (10%)

Unknown

4 (4%)

2 (5%)

61 (62%)

28 (72%)

5 (5%)

0 (0%)

33 (33%)

11 (28%)

No

12 (12%)

6 (15%)

Yes

80 (81%)

30 (77%)

7 (7%)

3 (8%)

8 (8%)

5 (13%)

SSRIs

13 (13%)

5 (13%)

Gabapentin

12 (12%)

6 (15%)

Infant race
Caucasian
American Indian

MAT

Breastfed
None
Exclusive
Some
Smoking

Unknown
#

Concurrent exposure
Benzodiazepines

Barbiturates
3 (3%)
1 (3%)
Concurrent exposure was considered positive if at least one of the following was met: 1)
infant drug screen was positive, 2) mother drug screen was positive, 3) mother admitted
drug use during pregnancy.
#
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Table 3.2 Summary of NAS outcomes in trial subjects (n=99) and clonidine-treated
subjects (n=39)
Trial subjects
Clonidine-treated
(treated + nontreated)
subjects
Outcome measures

Mean (SD) or N (%)

Mean (SD) or N (%)

Length of stay (LOS, days)

19.7 (11.1)

22.4 (7.60)

Length of primary treatment (days)

14.2 (10.2)

16.8 (6.59)

Need for pharmacologic treatment

81 (82%)

-

Need for adjunctive pharmacologic
treatment

21 (21%)

15 (38%)

Need for dose escalation of primary
treatment

55 (56%)

32 (82%)
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Table 3.3 Association between clinical variables and length of stay in days and days on primary treatment (n = 99)
Length of stay,
Treatment days,
Clinical variable
p-value$
p-value$
mean (SD)
mean (SD)
Preterm birth
No

19.9 (10.9)

Yes

19.5 (11.5)

0.88

14.4 (10.8)

0.73

13.1 (8.85)

Infant sex
Male

20.2 (10.8)

Female

19.1 (11.4)

0.62

14.6 (10.7)

0.67

13.3 (9.53)

MAT
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Buprenorphine

20.5 (11.0)

Methadone

17.8 (9.13)

0.50

14.3 (9.49)

0.57

12.5 (9.49)

Breastfed
None

20.9 (12.0)

Some or exclusive

17.9 (9.18)

0.20

14.8 (10.6)

0.29

12.8 (9.52)

Smoking

#

No

22.2 (14.1)

Yes

19.6 (10.8)

Benzodiazepines

0.45

17.3 (14.6)

0.29

13.7 (9.52)
0.17

No

19.3 (10.8)

13.6 (9.78)

Yes

24.9 (13.8)

19.2 (13.4)

0.15

Table 3.3 (continued)
Length of stay,
mean (SD)

p-value$

Treatment days,
mean (SD)

p-value$

No

19.1 (10.6)

0.15

13.7 (10.5)

0.26

Yes

23.8 (13.5)

Clinical variable
#

#

#

SSRI
16.1 (7.40)

Gabapentin
No

18.6 (9.80)

Yes

28.3 (15.7)

0.004*

13.3 (9.76)

0.014*

20.1 (11.7)

Barbiturates
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No

19.7 (11.1)

0.72

14.0 (10.1)

0.84

Yes
22.0 (13.1)
15.3 (15.5)
#
Positive if at least one of the following was met: 1) infant drug screen was positive, 2) mother drug screen was positive, 3) mother
admitted drug use during pregnancy. $Evaluated using univariate linear regression.

Table 3.4 Association between clinical variables and need for pharmacologic treatment and need for adjunctive pharmacologic
treatment (n = 99)
Need for treatment,
Need for adjunctive treatment,
Clinical variable
p-value$
p-value$
N (% of total)
N (% of total)
Preterm birth
No

54 (81%)

Yes

27 (84%)

0.65

18 (27%)

0.057

3 (9.4%)

Infant sex
Male

47 (84%)

Female

34 (79%)

0.54

13 (23%)

0.58

8 (19%)

MAT
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Buprenorphine

57 (84%)

Methadone

6 (75%)

0.54

17 (25%)

0.99

0 (0%)

Breastfed
None

52 (85%)

Some or exclusive

29 (76%)

0.27

18 (30%)

0.017*

3 (7.9%)

Smoking
No

11 (92%)

Yes

65 (81%)

0.39

2 (17%)
18 (23%)

0.65

Table 3.4 (continued)
Need for treatment,
N (% of total)

p-value$

Need for adjunctive treatment,
N (% of total)

No

74 (81%)

0.67

16 (18%)

Yes

7 (88%)

Clinical variable
#

p-value$

Benzodiazepines

#

#
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#

0.008*

5 (63%)

SSRI
No

69 (80%)

Yes

12 (92%)

0.31

17 (20%)

0.37

4 (31%)

Gabapentin
No

70 (80%)

Yes

11 (92%)

0.36

15 (17%)

0.015*

6 (50%)

Barbiturates
No

79 (82%)

0.50

20 (21%)

0.61

Yes
2 (67%)
1 (33%)
Positive if at least one of the following was met: 1) infant drug screen was positive, 2) mother drug screen was positive, 3) mother
admitted drug use during pregnancy. $Evaluated using logistic regression.

#

Table 3.5 Association between clinical variables and need for dose escalation (n = 99)
Need for dose escalation,
Clinical variable
p-value$
N (%)
Preterm birth
No

40 (74%)

Yes

15 (56%)

0.096

Infant sex
Male

34 (72%)

Female

21 (62%)

0.32

MAT
Buprenorphine

39 (68%)

Methadone

5 (83%)

0.46

Breastfed
None

35 (67%)

Some or exclusive

20 (69%)

0.88

Smoking

#

#

#

#

No

8 (73%)

Yes

43 (66%)

0.67

Benzodiazepines
No

49 (66%)

Yes

6 (86%)

0.31

SSRI
No

45 (65%)

Yes

10 (83%)

0.23

Gabapentin
No

45 (64%)

Yes

10 (91%)

0.11

Barbiturates
No

53 (67%)

Yes

2 (100%)

0.99

Positive if at least one of the following was met: 1) infant drug screen was positive, 2) mother drug screen
was positive, 3) mother admitted drug use during pregnancy. $Evaluated using logistic regression.

#
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3.3.3

SNP Associations

The genotype and allele frequencies of OPRM1 rs1799971 and COMT rs4680
among trial patients and those of GNB3 rs5443 and ADRA2A rs1800544 among clonidinetreated patients are summarized in Table 3.6. OPRM1 rs1799971 genotype was unable to
be determined for 1 untreated subject, likely due to low quality of this subject’s DNA
sample. The distribution of allele frequencies did not significantly deviate from what was
reported in the 1000 Genomes project for the CEU population (Table 3.6).
Results from unadjusted analysis using two-sample t-test on continuous variables
or Fisher’s exact test on categorical variables are summarized in Tables 3.7 – 3.10. Table
3.7 and Table 3.8 summarize results from two-sample t-tests between genotypes and LOS
or length of treatment assuming a dominant or recessive model. None of the tested
association reached experiment-wise statistical significance at α=0.0125. For the GNB3
825C>T SNP, TT carriers had a shorter LOS than CC/CT carriers (19.2 vs. 22.9 days,
p=0.045), but the number of patients with TT genotype was small (n=5). Tables 3.9 and
3.10 summarize results from Fisher’s exact tests between genotypes and categorical
outcomes assuming a dominant or recessive model. As is evident from the tables, none of
the tested associations reached point-wise or experiment-wise statistical significance.
Given the negative results from unadjusted analyses on the SNPs, multivariate linear or
logistic regression was not attempted.
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Table 3.6 Genotype and allele frequencies
Trial patients
SNP

Number of
patients

OPRM1 118A>G
(rs1799971)

98

Allele
frequencies

Allele frequencies
(1000 Genomes)

AA: n=78 (80%)

A=89%

A=85%

AG: n=18 (18%)

G=11%

G=15%

AA: n=32 (33%)

A=52%

A=46%

AG: n=39 (39%)

G=48%

G=54%

0.089

Genotype
frequencies

Allele
frequencies

Allele frequencies
(1000 Genomes)

p-value

CC: n=18 (46%)

C=67%

C=64%

CT: n=16 (41%)

T=33%

T=36%

CC: n=23 (59%)

C=73%

C=76%

CG: n=11 (28%)

G=27%

G=24%

p-value

0.14

GG: n=2 (2%)

COMT 472G>A
(rs4680)
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Genotype
frequencies

99

GG: n=28 (28%)

Clonidine-treated patients
SNP

GNB3 825C>T
(rs5443)

ADRA2A -1291G>C
(rs1800544)

Number of
patients

39

0.62

TT: n=5 (13%)

39

GG: n=5 (13%)

0.55

Table 3.7 Unadjusted SNP association analysis on continuous outcomes (dominant model)
Trial patients
Outcome measure

COMT 472G>A
GG (n=28)

COMT 472G>A
AA/AG (n=71)

p-value#

OPRM1 118A>G
AA (n=78)

OPRM1 118A>G
AG/GG (n=20)

p-value#

LOS (day)

20.2 (9.80)

19.6 (11.6)

0.81

20.4 (11.4)

18.0 (9.26)

0.38

Length of
treatment (day)

14.3 (8.66)

14.1 (10.9)

0.95

14.7 (10.3)

13.0 (9.92)

0.53

Clonidine-treated patients
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#

Outcome measure

GNB3 825 C>T
CC (n=18)

GNB3 825 C>T
CT/TT (n=21)

p-value#

ADRA2A -1291
G>C GG (n=5)

ADRA2A -1291 G>C
CG/CC (n=34)

p-value#

LOS (day)

23.5 (7.01)

21.5 (8.13)

0.43

19.0 (3.61)

22.9 (7.94)

0.29

Length of
treatment (day)

17.0 (5.01)

16.6 (7.81)

0.86

14.2 (3.83)

17.2 (6.86)

0.35

Determined by two-sample t-test (assuming equal or unequal variance). Data are presented as mean (standard deviation).

Table 3.8 Unadjusted SNP association analysis on continuous outcomes (recessive model)
Trial patients
Outcome measure

COMT 472G>A
AA (n=32)

COMT 472G>A
AG/GG (n=67)

p-value#

OPRM1 118A>G
GG (n=2)

OPRM1 118A>G
AA/AG (n=96)

p-value#

LOS (day)

22.9 (14.6)

18.2 (8.64)

0.098

20.5 (6.36)

19.9 (11.1)

0.94

Length of
treatment (day)

16.6 (13.3)

13.0 (8.27)

0.17

16.0 (5.66)

14.3 (10.3)

0.82

Clonidine-treated patients

66
#

Outcome measure

GNB3 825C>T
TT (n=5)

GNB3 825C>T
CC/CT (n=34)

p-value#

ADRA2A -1291
G>C CC (n=23)

ADRA2A -1291 G>C
GG/GC (n=16)

p-value#

LOS (day)

19.2 (2.39)

22.9 (8.01)

0.045*

22.3 (7.80)

22.6 (7.56)

0.90

Length of
treatment (day)

14.4 (2.30)

17.1 (6.95)

0.098

17.1 (7.69)

16.4 (4.77)

0.74

Determined by two-sample t-test (assuming equal or unequal variance). Data are presented as mean (standard deviation).

Table 3.9 Unadjusted SNP association analysis on categorical outcomes (dominant model)
Trial patients
Outcome measure

COMT 472G>A
GG (n=28)

COMT 472G>A
AA/AG (n=71)

p-value#

OPRM1 118A>G
AA (n=78)

OPRM1 118A>G
AG/GG (n=20)

p-value#

Need for pharmacologic
treatment

24 (85.7%)

57 (80.3%)

0.77

67 (85.9%)

14 (70.0%)

0.11

Need for adjunctive
pharmacologic treatment

6 (21.4%)

15 (21.1%)

1

19 (24.4%)

2 (10.0%)

0.23

Need for dose escalation
of primary treatment

18 (64.3%)

37 (52.1%)

0.37

43 (55.1%)

12 (60.0%)

0.80

Outcome measure

GNB3 825 C>T
CC (n=18)

GNB3 825 C>T
CT/TT (n=21)

p-value#

ADRA2A -1291
G>C GG (n=5)

ADRA2A -1291 G>C
CG/CC (n=34)

p-value#

Need for adjunctive
pharmacologic treatment

7 (38.9%)

8 (38.1%)

1

1 (20.0%)

14 (41.2%)

0.63

Need for dose escalation
of primary treatment

16 (88.9%)

16 (76.2%)

0.42

4 (80.0%)

28 (82.4%)

1

Clonidine-treated patients
67
#

Determined by Fisher’s exact test. Data are presented as count (percentage).

Table 3.10 Unadjusted SNP association analysis on categorical outcomes (recessive model)
Trial patients
Outcome measure

COMT 472G>A
AA (n=32)

COMT 472G>A
AG/GG (n=67)

p-value#

OPRM1 118A>G
GG (n=2)

OPRM1 118A>G
AA/AG (n=96)

p-value#

Need for pharmacologic
treatment

26 (81.3%)

55 (82.1%)

1

2 (100%)

79 (82.3%)

1

Need for adjunctive
pharmacologic
treatment

10 (31.3%)

11 (16.4%)

0.12

0 (0%)

21 (21.9%)

1

Need for dose escalation
of primary treatment

19 (59.4%)

36 (53.7%)

0.67

2 (100%)

53 (55.2%)

0.50

Outcome measure

GNB3 825 C>T
TT (n=5)

GNB3 825 C>T
CC/CT (n=34)

p-value#

ADRA2A -1291
G>C CC (n=23)

ADRA2A -1291 G>C
GG/GC (n=16)

p-value#

Need for adjunctive
pharmacologic
treatment

2 (40.0%)

13 (38.2%)

1

9 (39.1%)

6 (37.5%)

1

Need for dose escalation
of primary treatment

3 (60.0%)

29 (85.3%)

0.21

19 (82.6%)

13 (81.3%)

1
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Clonidine-treated patients

#

Determined by Fisher’s exact test. Data are presented as count (percentage).

3.4

Discussion
The first goal of this analysis was to explore the potential association between

OPRM1 rs1799971/COMT rs4680 with NAS disease severity/treatment outcomes as
reported by Wachman et al.112 OPRM1 rs1799971 and COMT rs4680 were shown to affect
opioid consumption or opioid efficacy in pain in some adult studies.125 However, in the
context of NAS, the association findings reported by Wachman et al. have not been
replicated by other investigators. In a small study by Mactier et al.,113 the authors did not
find significant relationship between these two SNPs and need for treatment in NAS
patients. Our analysis had a slightly larger sample size than the original study by Wachman
et al.112 Additionally, instead of only assuming one genetic model as in the previous study,
both recessive and dominant genetic models were attempted. In terms of baseline
demographics, the two studies had similar gender and race composition of neonates and
similar proportion of maternal tobacco use during pregnancy. The greatest difference of
the two populations was in the type of opioids used by the mothers during pregnancy. In
the study by Wachman et al., all mothers of the enrolled infants were on MAT (64%
methadone, 36% buprenorphine).112 While in our study, 69% of the mothers were on MAT
with buprenorphine, 8% were on MAT with methadone, and a larger proportion of the
mothers were likely polydrug users. Additionally, treated patients in the study by
Wachman et al. received either morphine or methadone, and the diagnosis criteria,
treatment protocol and care model used also differed from those used in our study. These
differences, along with the many intrinsic limitations of genetic association studies that
predispose them to false-positive and false-negative results, and the lack of a direct
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measure of NAS severity phenotypes, all likely contributed to our inability to replicate
previously reported associations.
GNB3 rs5443 and less so ADRA2A rs1800544 were associated with differential
response to clonidine treatment in a variety of disease states. However, they have never
been studied before in NAS. Clonidine has mostly been used as an adjunctive treatment in
NAS. Our evaluation of clonidine as a primary treatment can benefit greatly from
identification of genetic markers that could inform selection of patients who are more
likely to respond to clonidine. In this analysis, clonidine-treated patients with TT genotype
in GNB3 825C>T had an average LOS that was 3.7 days shorter than patients with CC/CT
genotypes, with a p-value that just reached point-wise significance. In this analysis the
sample size of clonidine-treated patients was relatively small. It would be interesting to
see whether the observed trend will hold in our extended analysis as the trial enrolls more
patients. Nevertheless, this analysis was also limited by the lack of a direct measure of
NAS severity phenotypes. The use of length of stay/treatment and proportion of patients
needing (adjunct) treatment as endpoints to evaluate treatment response (i.e., to quantify
pharmacodynamics of a drug) is suboptimal, as these measures could easily be confounded
by many clinical factors other than the drug effect.
Though genetic factors were not found to be statistically significant in our analysis,
we found significant associations between several clinical factors and one or more
measures of NAS severity, including breastfeeding, and maternal use of benzodiazepines
and gabapentin during pregnancy. This was in agreement with previous findings that
concomitant prenatal exposure to certain psychotropic medications could lead to increased
severity of NAS, and that breastfeeding was associated with decreased withdrawal
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severity.10 NAS babies exposed to these psychotropic mediations oftentimes underwent
prolonged withdrawal from these substances, which could be difficult to discriminate from
opioid withdrawal. While the benefit of breastfeeding could come from the act of
breastfeeding or the actual breast milk, most of the breastfed babies in our study received
a mixture of formula and breastmilk, and therefore the less severe phenotype of neonates
who were breastfed to any extent was probably best explained by the positive effect of
maternal presence and engagement.126 On the other hand, the association between type of
opioids used by the mother (methadone vs. buprenorphine) and disease severity was not
found in this analysis, perhaps due to the limited number of mothers who used methadone
during pregnancy. Overall, within the scope of this analysis, we could reach the conclusion
that clinical factors were more important predictors of NAS severity/treatment outcomes
than the genetic factors evaluated.
Our analyses have several limitations. First is the limited sample size. Genetic
studies need a large sample size in order to investigate multiple genetic variants with
enough statistical power, but admittedly recruiting a large number of subjects in neonate
clinical trials can be very challenging. As the No-POPPY trial continues to enroll patients,
this analysis will be extended to cover an expected total of 250 trial patients (including
100 clonidine-treated patients). A preliminary power calculation based on observed
standard deviation and differences in LOS found that inclusion of 123 trial subjects with
AA genotype in COMT 472G>A and 262 trial subjects with AG/GG genotypes in OPRM1
118A>G would be needed to meet point-wise significance in LOS for these two SNPs;
inclusion of 23 clonidine-treated subjects with GG genotype in ADRA2A -1291C>G would
be needed to meet point-wise significance in LOS. These projected sample sizes would be

71

difficult to achieve with the current enrollment goal. The second limitation is the
generalizability of our findings, which is the most challenging aspect for genetic studies
in NAS for several reasons. First, there is a lack of consensus on standardized NAS severity
phenotypes.14 The use of LOS as the primary outcome is prevalent, but is far from ideal.
In our analysis and work by others, effort has been made to adjust for potential effect of
some demographic and clinical factors on LOS, However, LOS (and similarly length of
treatment) is also highly influenced by many aspects in hospital care models, such as the
availability and type of non-pharmacologic care, the NAS assessment tool used, and sitespecific treatment protocols. The use of other endpoints, such as need for treatment and
need for adjunctive treatment, can be equally problematic. Both endpoints are highly
dependent on site-specific diagnostic criteria, treatment protocols, and types of primary
and secondary treatment agents used. Similarly, though the amount of replacement opioids
used and subjects’ scores on NAS scoring systems were used as outcome measures in some
previous studies, these two measures were also highly protocol- and institution-dependent.
Overall, findings from genetic association analyses should be interpreted within specific
NAS clinical practice settings.14 Nevertheless, genetic studies hold the promise of
individualizing treatment regimen if association between certain genetic variants and
differential response to treatment agents can be corroborated despite the abovementioned
challenges.
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CHAPTER 4. POPULATION PHARMACOKINETICS OF CLONIDINE AND
MORPHINE IN NAS
4.1

Introduction
Clinically used treatment protocols in NAS are largely empirical. While the primary

goal of most clinical trials in NAS focused on comparing the efficacy between two
pharmacologic agents, we should also recognize that results from these comparative
effectiveness studies should be interpreted within the context of institution-specific care
models and treatment protocols, and the favorable effect of one agent versus another
observed in some of these trials could be partially accounted for by optimization of
treatment protocols.26,127 As an example of how population modeling approach can be used
to optimize dosing regimen in NAS, Hall et al.128 showed in a pre-post cohort study that a
pharmacokinetically optimized methadone dosing protocol proposed by Wiles et al.129
resulted in a 3-day reduction in length of treatment compared to their original dosing
protocol.
In-depth understanding of the clinical pharmacology is essential for formulating
evidence-based treatment protocols. To this end, this introduction section will first provide
an overview of developmental pharmacokinetics in neonates, then delve into the details on
clinical pharmacology of morphine and clonidine, and subsequently review the study
objectives of this chapter.
4.1.1

Developmental Pharmacokinetics in Neonates

Children and adults respond differently to drugs due to differing pharmacokinetics
(PK) and pharmacodynamics (PD), with PK referring to the processes of drug disposition
in the body (i.e., absorption, distribution, metabolism and elimination), and PD referring
to the body’s physiological and biological response to the therapeutic agent.130
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Developmental changes in childhood comprise maturation of enzyme pathways (related to
PK), as well as expression and activity of receptors and proteins (related to PD).130 Such
maturation processes are often non-linear and do not correlate with body weight alone, and
therefore linear extrapolations from adult dosing to pediatric dosing based on body weight
(i.e., the linear per kilogram model) is often an over-simplification and may lead to underor overdosing.130 Since pediatric studies often involved sparse sampling and unbalanced
design, population approach with non-linear mixed effect modeling is the preferred tool to
study PK and PD parameters. The power of the population approach lies in its ability to
use all available individual data to estimate population mean of the parameters, as well as
estimating the inter- and within-individual variability.131 The resulting models, once
validated, can be used to derive rational dosing schemes that are predicted to be safe and
effective, which in turn can be challenged and tested in prospective clinical trials.130
Using the population approach, the effect of developmental changes in children can
be investigated mainly by testing size (body weight) and/or age as predictors (covariates)
of PK/PD variability.130 Size can be incorporated in the model either a priori by allometric
scaling (fixed allometric model), or as a covariate as any other (systematic covariate
model).130 Allometric scaling relations have been used to describe how biological variables
change dependent on body mass. The use of 3/4 as the scaling exponent for metabolic rates
is well supported by theoretical and experimental evidence, and therefore it can be used as
the power parameter for drug clearance (CL).132 Volume of distribution (V) has been found
to be directly proportional to body weight, so 1 can be used as the scaling exponent for
volume terms.132 While the use of allometry can help explain the influence of body size, it
cannot fully explain the maturation trajectory of metabolizing enzymes, receptors and
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transporters, which contributes to considerable variability observed in neonates.133 For
example, the dominant CYP3A enzyme in the fetus is CYP3A7, and its level gradually
decreases after birth as expression of CYP3A4 increases.134 In fact, the majority of drug
metabolizing enzymes are expressed at low levels before birth, and their expression levels
mature within a few weeks in the case of CYP2D6, or within 1-2 years after birth in the
case of CYP1A2 and CYP3A4.134 Renal function and liver flow also mature as a function
of age.130 Additionally, body composition evolves continuously in childhood, which can
affect the volume of distribution of drugs. Neonates have much higher percentage of total
body water (80-90% of body weight) than adults (55-60% of body weight). As a result, for
hydrophilic drugs, a larger volume of distribution is observed in neonates than in adults.130
Therefore, influence of age should be explored next as a covariate, and postmenstrual age
(PMA), gestational age (GA), and postnatal age (PNA) can all be tested as age descriptors.
As an example, Holford et al.135 proposed a “standard approach” to model PK
parameters in children following Equations 1-2:
𝑊𝑊𝑊𝑊 3/4
𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
𝐶𝐶𝐶𝐶 = 𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠 × �
� ×
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠
𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 + 𝑇𝑇𝑇𝑇50 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
𝑉𝑉 = 𝑉𝑉𝑠𝑠𝑠𝑠𝑠𝑠 × �

𝑊𝑊𝑊𝑊
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠

(1)

(2)

where WTstd is usually set to 70 kg; CLstd and Vstd stand for clearance and volume
in a reference adult with weight of WTstd; PMA refers to postmenstrual age, TM50 refers
to the maturation half-life, and HILL stands for the Hill coefficient of the sigmoidal
maturation function.136 The authors proposed that PNA was not as a good predictor as
PMA, since most maturation processes start in utero.136 Maturation of clearance may also
be described with other functions, such as linear, exponential, and asymptotic exponential
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models; the advantages and disadvantages of which are discussed elsewhere.132 Changes
of volume of distribution in relation to age can occur due to changes in body composition,
and such changes may be described with similar functions as those used for clearance.132
Lastly, one needs to be cautious when interpreting the results from models
incorporating both body weight and age-dependent maturation: We could use such models
to predict when the parameter (e.g., CL and V) in neonates reach certain percentage of the
adult value, with body weight already taken into account using the weight function in the
model. For example, it was reported that the glomerular filtration rate (GFR) in mL/min/70
kg is 35% of the adult value in neonates and reaches adult value at around the age of 1
year.137 This should not be interpreted as the actual GFR value in children older than 1
year of age is the same as that in adults. Rather, based on this model, the actual GFR value
in children aged over 1 year continues to grow with weight, but this growth can be
explained by weight alone as age has been taken out of the equation.

4.1.2

Pharmacology and Pharmacokinetics of Morphine and Clonidine
4.1.2.1 Morphine Pharmacology

Morphine is a μ-opioid agonist used for treating moderate-to-severe pain. Its
binding to μ-opioid receptors is responsible for its therapeutic effect of analgesia, and
sedation, euphoria and respiratory suppression.138 Due to its relatively high hydrophilicity
and degree of ionization at physiological pH, brain penetration of morphine is delayed
(relative onset ~6 min), which manifests as a poor association between morphine plasma
concentration and analgesic affect.139 Glucuronidation of hydroxyl groups on 3- and 6positions mainly by UDP-glucuronosyltransferases (UGT) 2B7 produces morphine-376

glucuronide (M3G) and morphine-6-glucoronide (M6G).84 Multiple studies have shown
that M6G is a strong μ-opioid agonist with analgesic properties that contribute
significantly to analgesic effect of morphine, and it appears to have less respiratory
depressant effect than morphine.140 In contrast to M6G, M3G has very low binding affinity
for μ-opioid receptors with no analgesic properties.141
4.1.2.2 Morphine PK in Adults
Morphine undergoes extensive hepatic first-pass metabolism, leading to relatively
low bioavailability (~20-30%).142 Time to the maximum plasma concentration (tmax) is
approximately 1 h after oral dosing.143 Its distribution has been modeled by one, two and
three compartments in reported literature, and studies that had the longest and most
frequent sample collection tend to favor three-compartment models.142 Reported steadystate volume of distribution ranges from 1 to 4 L/kg.144 90% of the dose is metabolized,
with an estimate of 45%-55% of the dose converted to M3G and 10%-15% to M6G, and
the rest to minor metabolites including normorphine, morphine-3,6-diglucuronide,
morphine-3-ethereal sulfate, normorphine-6-glucuronide, normorphine-3-glucuronide and
codeine.85 The route of administration has been reported to affect the M3G/M6G to
morphine plasma AUC ratios, indicating these glucuronide metabolites are formed from
both first-pass effect and systemic clearance.145 Estimated total clearance ranges from 75
to 118 L/h,142 which supports that morphine has a high hepatic extraction ratio. Estimated
elimination half-life ranges from 1.4 to 2.7 h.145,146 M3G and M6G are both eliminated by
the kidney, and the exposure to both metabolites increases in renal impairment.147
4.1.2.3 Morphine PK in Neonates
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Compared to adults, clearance of morphine is lower in neonates due to immature
glucuronidation capacity, but it is well established that term neonates are able to
metabolize morphine to M3G and M6G.148 Compared to adults, renal excretion of
unchanged morphine accounts for a higher proportion of total body clearance in term
neonates (~19%).148
Studies in neonates and children have found that morphine clearance on a linear per
kg basis increases with age and reaches adult values between 1 and 6 months of age.148-150
A meta-analysis by Kart et al.

148

on estimated PK parameter values in the pediatric

population reported that the mean volume of distribution was 2.8 L/kg in neonates and
children regardless of the age, which is in the range of the adult value on a linear per kg
basis. Pooled estimates of half-life were 9.0 hours and 6.5 hours in preterm neonates and
term neonates aged 0-57 days, which were significantly longer than adult adults.148
Correspondingly, pooled estimates of clearance ranged from 2.2 to 8.1 mL/min/kg (0.13
to 0.49 L/h/kg) in preterm neonates and term neonates, respectively.148 It is apparent that
in neonates weight-normalized morphine clearance increases with gestational and
postnatal age, though there exists interindividual variability.148
A number of population PK models for morphine have been proposed in the
pediatric population that included neonates. However, they differed in terms of the number
of compartments for the parent compound and/or the glucuronide metabolites,
parameterization of allometric equations, how/which age descriptors were incorporated
into clearance and/or volume, and what maturation functions were used. Comparative
performance of these models and other published pediatric PK models in describing
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pediatric morphine PK observations has been studied elsewhere with divergent
conclusions.151-153
Liu et al.154 reported a morphine population PK model based on 88 blood samples
collected from 34 neonates with NAS who were given DTO orally (containing 0.04 mg
morphine per mL).87 Prior to this report, there had only been studies of morphine PK
following intravenous administration in pediatric patients. In the development of the
population PK model, the authors used data from adult patients who received intravenous
morphine and rich sampling scheme.155 They started with a three-compartment model used
in the adult study, followed by addition of allometric scaling to PK parameters. Maturation
of clearance based on PMA using a sigmoidal maturation model and maturation of central
volume based on PNA using an exponential model were also used. Lastly the model
included the addition of first-order absorption rate constant and bioavailability
parameters.154 Standardized clearance, central volume, and the two peripheral volumes
were estimated to be 75.3 L/h/70 kg, 17.8 L/70 kg, 87.3 L/70 kg, and 199 L/70kg,
respectively.154 Absorption rate constant and bioavailability were estimated to be 0.751/h
and 48.5%, and the authors confirmed the findings by Holford et al. 152 that time to reach
50% of adult value of clearance was 58.3 weeks PMA, and that of central volume was 9.65
weeks PNA (standardized to a 70 kg person). The authors commented that the estimated
bioavailability was higher than in adults likely due to a lower first-pass effect, which,
together with lower systemic clearance, can be explained by lower expression of UGT2B7
and smaller liver size in neonates and correspondingly lower glucuronidation capability.154
4.1.2.4 Clonidine Pharmacology
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Clonidine is a centrally-acting anti-hypertensive agent, and it is also clinically used
in pediatric anesthesia as premedication or an analgesic.156 It is an imidazole compound
that acts as a selective partial agonist at α2-adrenergic receptors, and its cardiovascular
effects are thought to be mediated through stimulation of α2-inhibitory neurons in the
medulla oblongata that leads to reduction in noradrenergic neurotransmission.94 Clonidine
stimulates presynaptic α2-adrenergic receptors and decreases norepinephrine release and
consequently peripheral sympathetic output to the heart and vasculature.94 Additionally, it
exerts its sedative effect in the locus coeruleus where it inhibits the spontaneous firing of
the nucleus, leading to CNS suppression.156

4.1.2.5 Clonidine PK in Adults
Clonidine is highly bioavailable and readily absorbed; reported mean
bioavailability values are from 75 to 90%, and tmax occurs between 1.5 and 2.5 hours.157,158
Clonidine is highly lipophilic, and it can readily penetrate the blood-brain barrier and enter
extravascular space.159 Its disposition has been described with two-compartment models,
and the reported volume of distribution ranges from 2 to 5 L/kg.157,158 Entero-hepatic
circulation was reported by Arndts et al., who observed a resurgence of plasma
concentrations 15-20 minutes after a meal.160 About 40-60% of a dose is excreted
unchanged in the urine, while the remainder is metabolized to inactive metabolites
primarily by CYP2D6.159 The renal clearance is estimated to approximately 7.6 L/h (127
ml/min) with significant variability, which exceeds the glomerular filtration rate in some
subjects.158 Dose-dependent kinetics have been observed in some studies, where one study
reported that the systemic clearance decreased from 24 to 13 L/h (5.8 to 3 ml/min/kg) when
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the intravenous dose administered increased from 75 to 275 μg.161 Another study by the
same group reported that at an intravenous dose of 0.78 μg/kg, systemic clearance was
estimated to be 42 L/h (10 mL/min/kg), while as the intravenous increased from 1.27 to
3.36 μg/kg, clearance estimate decreased to a much smaller degree from 16.8 to 10.9 L/h
(4 to 2.6 mL/min/kg).157 Overall the reported elimination half-life ranges from 6 to 13
hours.157,158
4.1.2.6 Clonidine PK in Neonates
Age may affect the clearance of clonidine by impacting the development of GFR
and CYP2D6 mediated metabolism.162 CYP2D6 expression and activity develop rapidly
in the first week of life, and age did not significantly affect CYP2D6 expression or activity
levels among postnatal liver samples from subjects greater than 7 days of age.163 In
contract, standardized GFR rises steadily after an initial rapid increase, reaching adult
values at 8 to 12 months of age.164
Using data from published PK studies in children who received intravenous, rectal
or epidural clonidine (380 observations from 72 subjects, aged 0-14 years), Potts et al. 159
reported a population PK model incorporating allometric scaling of PK parameters and
asymptotic exponential maturation of clearance based on PNA. A two-compartment model
was used for data fitting, and the normalized parameter estimates for 70-kg adults were
14.6 L/h for clearance, 62.5 L for central volume, and 119 L for peripheral volume. These
standardized values are close to reported values in adult studies. Clearance at birth
standardized for weight was estimated to be 3.8 L/h/70 kg, and maturation half-life was
estimated to be 25.7 weeks.159 The reduced clearance in pediatric population was attributed
to immaturity of elimination pathways. The authors concluded that this maturation half81

life reported from their model was consistent with the development timeline of the renal
system.159
Xie et al. 107 reported a population PK model based on 102 PK observations from
36 NAS neonates treated with oral clonidine. A one-compartment model was used. The
apparent clearance was modeled with an allometric power model combined with a sigmoid
maturation model based on PNA, and the apparent volume was modeled with an allometric
power model. For the final parameter estimates, the absorption rate constant was 0.533/h,
the apparent clearance and the apparent volume for a typical adult weighing 70 kg were
15.2 L/h and 391 L respectively.107 Based on this model, typical values of apparent
clearance, apparent volume and half-life for neonates weighing 2.9 kg and aged 7.5 days
were estimated to be 0.27 L/kg/hour, 5.6 L/kg and 14.2 hours.107 While the standardized
value of clearance was close to previous reported values, the maturation half-life was
estimated to be 4.1 days, and the estimated time to reach 70% weight-adjusted adult value
of clearance was 1 month, compared with 9 months according to the findings by Potts et
al.107,159 It was postulated that this discrepancy is due to different age distributions in the
two studies, as in the study by Potts et al. only a small number of subjects were neonates.159
4.1.3

Study Objectives

The first goal of this analysis was to construct population PK models of clonidine
and morphine and evaluate the effect of clinical factors and genetic factors on drug
disposition. While important clinical factors such as body weight and age were assessed
in previous population PK studies in NAS patients, potential effect of genetic factors has
never been studied in this population. Approximately 50% of the clonidine dose is
metabolized through CYP2D6 and 50% is renally excreted. Thus, CYP2D6 metabolizer
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class was considered as a covariate in clonidine population PK model building. For
morphine, OCT1 and ABCC3 are among the transporters shown to significantly affect the
disposition of the parent compound and/or its metabolites based on in vitro and in vivo
studies. OCT1 has been shown to mediate hepatic uptake of morphine, and homozygous
loss-of-function OCT1 variants (OCT1*2-*5/*2-*5) were associated with lower morphine
clearance.165,166 On the other hand, ABCC3 is an efflux transporter expressed in liver
basolateral membranes and effluxes M3G and M6G into the bloodstream.166 The ABCC3
−211C>T (rs4793665) TT genotype is associated with lower mRNA expression in the liver
tissue, and subjects with CC genotype were found to have significantly higher M3G and
M6G formation than subjects with CT and TT genotypes.166 Therefore, OCT1 class and
the ABCC3 −211C>T were evaluated as covariates in morphine population PK model
building. The second goal of this analysis was to use the population PK model to perform
simulation studies to inform dosing selection. As PK of clonidine are not as well studied
as morphine in pediatric patients, this part of the analysis was focused on optimization of
clonidine dosing in NAS patients.

4.2

Clonidine Population Pharmacokinetic Modeling
4.2.1

Methods
4.2.1.1 Trial Subjects

Clonidine-treated subjects enrolled in the No-POPPY trial (NCT03396588) from
the start of trial (December 2017) to February 2020 with PK samples collected were
included in this analysis. Details of the trial design are discussed in Section 1.6. Subjects
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randomized to the clonidine treated group received clonidine 8.3 µg/mL oral suspension,
which was compounded by the hospital pharmacy using clonidine oral tablets.
4.2.1.2 Sample Collection
For PK analysis, up to five blood samples were collected from each treated patient
in EDTA blood tubes using heel sticks. Of the five blood samples, three were collected at
random timepoints on different days during treatment, one was collected within 0-4 hours
after the final dose, and one was collected between 4-12 hours after the final dose. After
collection, blood samples were refrigerated until processing, where blood samples were
centrifuged at 2500g for 15 min at 4 °C for plasma separation. Plasma samples were stored
at -80 °C until analysis. The clonidine concentration in plasma samples was quantified
using validated LC/MS-MS methods as detailed in Chapter 2.
4.2.1.3 SNP Genotyping
Patient DNA samples were genotyped for CYP2D6 alleles with null function (*4)
and alleles with reduced function (*9, *10, *41) using commercially available TaqMan®
SNP

Genotyping

[2615AAG>del],

Assays

(C__27102431_D0

C__11484460_40

[100C>T],

[1846G>A],

C__32407229_60

C__34816116_20

[2988G>A]),

respectively (Thermo Fisher Scientific). Of note, as 100C>T is part of both CYP2D6*4
and CYP2D6*10, the presence of 100C>T in combination with the absence of 1846G>A
is diagnostic of CYP2D6*10.167 The *5 allele (whole gene deletion) and the presence of
multiple gene copies were determined using the FAM-labeled CYP2D6 TaqMan® Copy
Number Assay (Hs00010001_cn) with an internal control assay, VIC-labeled TaqMan®
Copy Number Reference Assay RNase P. Using these two assays, CYP2D6 copy number
variation was determined from four replicates of each sample using the 2-∆∆CT method.168
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∆CT was calculated from the average (CT,FAM – CT,VIC)sample, and ∆∆CT from average
(CT,FAM – CT,VIC)sample – average (CT,FAM – CT,VIC)calibrators, where calibrators were samples
with two copies of CYP2D6 alleles. As samples with two CYP2D6 alleles had relative
quantity of 1, the copy number of CYP2D6 for each sample was then calculated from 2×2∆∆CT

. Experimental details of SNP genotyping are described in Section 3.2.2.

CYP2D6 metabolizer class (ultrarapid metabolizer [UM], normal metabolizer
[NM], intermediate metabolizer [IM], poor metabolizer [PM]) was classified based on the
principle that the individual’s highest functioning CYP2D6 allele determines its
phenotypic activity.169 Specifically, possessing at least one fully functional allele results
in an NM phenotype, possessing two reduced function allele or one reduced and one null
allele results in an IM phenotype, and possessing only null allele(s) results in a PM
phenotype. UMs possess multiple copies of functional CYP2D6 alleles.
4.2.1.4 Dataset Assembly
To construct a dataset for PK analysis, patients’ dosing records were first obtained
from their electronic health records (EHR). The original dosing amount in EHR was
recorded in volume (mL) to maintain blinding of the trial, which was converted to
amount (µg) in data processing. Clonidine concentrations measured from the LC/MS-MS
assay were manually added into the dataset as the dependent variable. Demographic and
clinical data for each subject were obtained from REDCap electronic data capture tools
hosted at University of Kentucky,170,171 including gestational age (GA, days), postnatal
age (PNA, days), postmenstrual age (PMA, days), mode of delivery, preterm birth (GA <
38 weeks), gender, race and daily weight. Missing values of daily weight were imputed
using the last observation carried forward (LOCF) method. CYP2D6 metabolizer class of
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each subject was manually assigned and added into the dataset. Dataset merging and
manipulation steps were performed in R (ver. 3.6.2, The R Foundation for Statistical
Computing, Austria) under R Studio environment (ver. 1.2.5019).
4.2.1.5 Population PK Model Building
All modeling steps were performed using first-order conditional estimation (FOCE)
with interaction in NONMEM (ver. 7.3, ICON Development Solutions, MD, USA) and
PsN (ver. 4.8.1 Uppsala University, Sweden) on original concentration data. Exploratory
graphs were generated using ‘ggplot2’ package in R.
4.2.1.5.1 BASE MODEL DEVELOPMENT
First, one or two compartment base models with first-order absorption and
elimination were explored. The following residual error models were explored: additive,
proportional and combined additive and proportional. Interindividual variability (IIV) was
assumed to be log-normal with mean 0 and variance of ω2 as follows:
𝜃𝜃𝑖𝑖 = 𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑒𝑒 𝜂𝜂𝑖𝑖 (3)

where θi is the value of a PK parameter for subject i, θTypical is the typical value of
that parameter in the population, and ηi is the interindividual random effect. IIV was
retained in the model if it was well estimated (coefficient of variation [%CV] < 50%). The
base model was selected based on objective function value (OFV) between nested models.
A decrease of OFV of greater than 9.21 (df=2, p<0.01) was needed to select a twocompartment over a one-compartment model. Additionally, a base model was accepted
only if model minimization was successful and adequate precision of parameter estimates
(CV<50%) could be achieved.
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4.2.1.5.2 COVARIATE MODEL DEVELOPMENT
Based on the standardized PK approach for pediatric subjects proposed by Holford
et al.,135 after the base model was selected, allometric scaling was incorporated a priori
into the PK parameters standardized to 70 kg adults, using fixed allometric exponents (0.75
on clearance terms and 1 on volume terms):
𝑊𝑊𝑊𝑊𝑖𝑖 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒 𝜂𝜂
𝜃𝜃𝑖𝑖 = 𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 �
𝑒𝑒 𝑖𝑖 (4)
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠

where 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒 is the allometric exponent, 𝑊𝑊𝑊𝑊𝑖𝑖 is the weight of subject i, 𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠 is the

standard weight of an adult (70 kg). Subsequently, univariate analysis was performed on

each covariate. Age measures (PNA, PMA, GA) were tested on PK parameters using a
sigmoidal maturation model (Equation 5) or power model (Equation 6):
𝜃𝜃𝑖𝑖 = 𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 × �

𝑊𝑊𝑊𝑊𝑖𝑖 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒
𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
𝜂𝜂𝑖𝑖
× � 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
�
𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 � × 𝑒𝑒 (5)
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠
𝑇𝑇50
+ 𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖

𝑊𝑊𝑊𝑊𝑖𝑖 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒
𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖
𝜃𝜃𝑖𝑖 = 𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 × �
×�
�
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐶𝐶𝐶𝐶𝐶𝐶)

𝜃𝜃𝑐𝑐𝑐𝑐𝑐𝑐

× 𝑒𝑒 𝜂𝜂𝑖𝑖 (6)

where 𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖 is the value of the covariate for subject i, HILL and T50 are the hill

coefficient and maturation half-time in the sigmoidal maturation model, respectively; in
the power model 𝜃𝜃𝑐𝑐𝑐𝑐𝑐𝑐 stands for the effect of covariate on parameter θ.

Categorical variables (gender, preterm birth, mode of delivery, race, CYP2D6 class)

were tested on PK measures using the following equation:
𝑊𝑊𝑊𝑊𝑖𝑖 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒
𝜃𝜃𝑖𝑖 = 𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 × �
× 𝑒𝑒 𝜃𝜃𝑐𝑐𝑐𝑐𝑐𝑐×𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖 × 𝑒𝑒 𝜂𝜂𝑖𝑖 (7)
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠

where 𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖 is the value of the covariate for subject i coded as 0 or 1. While race

and CYP2D6 class were not dichotomous variables in the original dataset, as most of the
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subjects were Caucasian and most of them were categorized as extensive CYP2D6
metabolizer, in NONMEM these two variables were coded as Caucasian versus other races,
and extensive metabolizer versus other types of metabolizers, respectively.
In univariate analysis, a cutoff of 6.64 (df=1) or 9.21 (df=2) in ∆OFV,
corresponding to a significance level of 0.01, was used to determine the statistical
significance of a covariate. Covariate effect was explored on PK parameters whose eta
shrinkage was relatively small (<30%).172,173 For age effect on PK parameters, as there
were multiple measures available tested in two different models (sigmoidal maturation and
power models), OFV was used to compare nested models; the Akaike information criterion
(AIC), calculated from OFV + 2p (p=the number of evaluated parameters), was used to
compare non-nested models. Additionally, precision of model parameter estimates was
also considered in covariate model development. If multiple covariates were found to be
statistically significant, stepwise covariate selection would be performed using 0.01 as the
p-value for forward selection and 0.001 as the p-value for backward elimination to result
in the final model.
4.2.1.5.3 MODEL EVALUATION
Routine diagnostic plots produced from ‘xpose’ package in R, including dependent
variable (DV, clonidine concentration in ng/mL) vs. population predicted value (PRED),
DV vs. individual predicted value (IPRED), conditional weighted residuals (CWRES) vs.
TIME, and CWRES vs. PRED.
Model stability was evaluated by performing 1000 nonparametric bootstrap runs in
PsN. Median value and 95% confidence intervals based on percentile of the empirical
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distribution of parameters generated from the bootstrap runs were compared with the
parameter estimates and parametric 95% confidence intervals based on the final model.
Prediction-corrected visual predictive check (VPC) was generated in PsN based on
1000 simulations to evaluate the performance and predictive ability of the final model.

4.2.1.5.4 DOSE SIMULATIONS
Simulation datasets with 200 simulated subjects with demographic data (including
daily weight) randomly drawn from 40 patients in the original study were created in R for
each of the following dosing regimens: 1 µg/kg every 3 hours (the original starting dose
of the No-POPPY study), 1 µg/kg every 3 hours with a loading dose of 3 µg/kg, and 1
µg/kg every 3 hours with a loading dose of 5 µg/kg. Monte Carlo simulations for each of
the three dosing regimens were performed in NONMEM. Concentration profiles simulated
after treatment initiation were evaluated against a minimum target concentration level,
with the goal of achieving higher probability of symptom stabilization in early treatment
period.
4.2.2

Results
4.2.2.1 Demographics

Among the subjects who received clonidine as the primary treatment and had PK
samples taken, two subjects were removed from the analysis due to protocol violation. A
total of 175 PK observations from 40 subjects were incorporated in the dataset. Of the 175
PK observations, 15 (9%) were below the lower limit of quantification (LLOQ). Because
the proportion of observations below the LLOQ was low, these observations were removed
from PK analysis.
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Subject demographics at baseline and at PK observations are summarized in Table
4.1. The subjects included in this analysis were mostly Caucasian. At baseline (start of
treatment), the average PNA was 2.68 days, meaning that these babies were started
pharmacologic treatment fairly quickly after birth. The average GA was 272 days, as only
late preterm and term neonates were allowed in this trial. At PK observations, PNA of the
subjects ranged from 1 to 50 days, and the PMA ranged from 254 to 328 days. Table 4.2
summarizes the distribution of CYP2D6 metabolizer class and genotypes. 37 out of 40
subjects (92.5%) were classified as extensive metabolizers.
The observed clonidine concentration-time profiles are presented in Figure 4.1,
where the dashed vertical lines represent the typical dosing interval. The original clonidine
concentration is plotted against time after dose in the upper panel, and dose-normalized
concentration is plotted against time after dose in the lower panel. In the lower panel, the
data points taken within the typical dosing interval (0-3 hr) or >3 hr after dose do not show
a clear increasing or decreasing trend.
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Table 4.1 Demographics for clonidine subjects in population PK model development
Baseline demographics (40 subjects)
Count (%) or Mean (SD)
Infant sex, male

24 (60%)

Race
Caucasian

32 (80%)

American Indian

1 (2.5%)

Multiple

5 (12.5%)

Missing

2 (5%)

Preterm birth (GA<38 weeks)

10 (25%)

Mode of delivery, vaginal birth

22 (55%)

Birthweight (kg)

3.16 (0.423)

Postnatal age (PNA, day)

2.68 (1.24)

Gestational age (GA, day)

272 (8.08)

Post-menstrual age (PMA, day)

274 (8.18)

Demographics at PK obs (n=175)

Median (Range)

Weight (kg)

3.26 (1.97-5.37)

Postnatal age (PNA, day)

12.4 (1.47-49.8)

Gestational age (GA, day)

273 (252-285)

Post-menstrual age (PMA, day)

283 (254-328)
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Table 4.2 CYP2D6 metabolizer class and genotype summary in clonidine subjects
Metabolizer class
Genotype
Count
Wt/Wt
15
Wt/*4
9
Extensive metabolizer (EM)
Wt/*5
4
n=37
Wt/*9
1
Wt/*10
1
Wt/*41
7
Intermediate metabolizer (IM) n=1
*4/*9
1
*4/*4
1
Poor metabolizer (PM) n=2
*4/*5
1
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Figure 4.1 Observed clonidine concentration-time profile. Only concentrations equal to or
above the lower limit of quantification (0.1 ng/mL) are included. Upper panel: Clonidine
concentration (ng/mL) vs. time after dose. Lower panel: Dose-normalized clonidine
concentration (1/L) vs. time after dose. Vertical dashed lines are marked at 3 hours (the
typical dosing interval).
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4.2.2.1 Base Model Development
One-compartment model with first-order absorption and elimination was fitted
successfully to the data. Modeling with mixed error or proportional error resulted in
significantly lower OFV than modeling with additive error. However, using the mixed
error model resulted in a miniscule and poorly estimated additive error. Therefore, a
proportional error model was selected. Two compartment models with different error
models were attempted. However, in these models the intercompartmental clearance (Q)
and/or volume of the peripheral compartment (V2) were approaching 0 without
improvement of the OFV. Therefore, subsequent covariate model development was based
on a one-compartment model with proportional error. Starting with this base model
without any IIV, addition of IIV on CL/F (apparent clearance) and IIV on V/F (apparent
volume of distribution) significantly decreased the OFV by 61.6. Both IIV terms were well
estimated (CV<50%) with relatively small eta shrinkages (6.8% and 33.0%, respectively).
Additional inclusion of the IIV on the first-order absorption rate constant (Ka) did not
further decrease the OFV by a significant amount, and it was poorly estimated. Therefore,
the IIV on CL/F and IIV on V/F were retained the base model (OFV = -131.9). Parameter
estimates for the base model are listed in Table 4.3.
Table 4.3 Parameter estimates for the base model of clonidine (OFV = -131.9)
Model Parameter
Estimate
Standard Error
RSE (%)
Structural Model
CL/F (L/hr)
0.713
0.0519
7.28
V/F (L)
10.2
1.80
17.6
-1
Ka (hr )
0.481
0.224
46.6
Interindividual Variability
ω2CL
0.154
0.0604
39.2
2
ωV
0.348
0.154
44.3
Residual Variability
σprop
0.324
0.0263
8.12
94

4.2.2.2 Covariate Model Development
As the first step, allometric scaling on CL/F and V/F was incorporated into the
model using fixed allometric exponents to account for the effect of weight. The
introduction of allometric scaling to the base model significantly decreased the OFV to 148.5 (∆OFV=-16.6; p<0.01). However, in this model the IIV on V/F was poorly estimated
(CV=54%). Therefore, only IIV on CL/F was retained in this intermediate model, which
had an OFV of -139.1. Further model development only evaluated potential covariate
effect on CL/F based on this intermediate model.
Next, univariate analysis was performed on age measures (PNA, PMA, GA) and
categorical variables (gender, preterm birth, mode of delivery, race, CYP2D6 class). Each
age measure was fitted using equations 5 and 6, and the OFV and AIC of each model are
presented in Table 4.4. With the sigmoidal maturation models, in addition to IIV on CL/F,
IIV on HILL was incorporated if it was well estimated and eta shrinkage was small.
Inclusion of IIV on T50 was attempted but it resulted in IIV estimates that were approaching
0. With either sigmoidal maturation model or power model, PNA appeared to be a better
measure than GA and PMA in terms of the goodness of model fits. When comparing all
six models, since the sigmoidal maturation models and the power models were non-nested,
AIC was used to select the best age covariate model, which used sigmoidal maturation to
describe the effect of PNA on CL/F.
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Table 4.4 Univariate analysis of age on apparent clearance of clonidine
Model description
OFV
Number of
parameters

AIC

PNA on CL/F (sigmoidal maturation) + IIV on
CL/F and IIV on HILL

-184.1

8

-168.1

GA on CL/F (sigmoidal maturation) + IIV on CL/F

-139.4

7

-125.4

PMA on CL (sigmoidal maturation) + IIV on CL/F
and IIV on HILL

-158.6

8

-142.6

PNA on CL/F (power model) + IIV on CL/F

-150.1

6

-138.1

GA on CL/F (power model) + IIV on CL/F

-139.4

6

-127.4

PMA on CL/F (power model) + IIV on CL/F

-141.7

6

-129.7

Univariate analysis with the categorical variables did not identify any covariates
that significantly decreased the OFV. Therefore, the final model selected was a 1compartment model with first-order absorption with allometric scaling on CL/F and V/F,
and PNA on CL/F with a sigmoidal maturation function, incorporating IIV on CL/F and
HILL and residual variability modeled as proportional error. Individual apparent clearance
and volume can be predicted using the following equations:
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑘𝑘𝑘𝑘) 0.75
𝑃𝑃𝑃𝑃𝑃𝑃 (𝑑𝑑𝑑𝑑𝑑𝑑)0.471
𝐶𝐶𝐶𝐶
= 13.6 × �
×�
� (8)
�
70
6.350.471 + 𝑃𝑃𝑃𝑃𝑃𝑃 (𝑑𝑑𝑑𝑑𝑑𝑑)0.471
𝐹𝐹
𝑉𝑉
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑘𝑘𝑘𝑘)
= 385 × �
� (9)
𝐹𝐹
70

Final model parameter estimates are presented in Table 4.5. Relative standard error
(RSE) of all model parameter estimates are <50%, indicating they were estimated with
good precision. Maturation half-life of CL/F was estimated to be 6.35 days, indicating that
the apparent clearance standardized to 70 kg adults matured rapidly after birth and reached
half of the adult value at PNA of 6 days, after adjusting for the weight effect on clearance
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using allometric scaling. Of note, the IIV for HILL is large (CV~192%), which reflected
large interpatient variability in individual clearance maturation trajectory.

Table 4.5 Parameter estimates for the final model of clonidine (OFV = -184.1)
Model Parameter
Estimate
Standard Error
RSE (%)
Structural and Covariate Model
CL/F per 70 kg (L/hr)
13.6
0.796
5.85
V/F per 70 kg (L)
385
23.7
6.16
-1
Ka (hr )
0.905
0.168
18.6
HILL
0.471
0.208
44.2
T50 (day)
6.35
0.188
2.96
WT on CL/F
0.75 (fixed)
WT on V/F
1 (fixed)
Interindividual Variability
ω2CL
0.128
0.0305
23.8
ω2HILL
3.68
1.55
42.1
Residual Variability
σprop
0.265
0.0202
7.6
4.2.2.3 Model Evaluation
Routine diagnostic plots of the final model are shown in Figure 4.2. In the DV vs.
PRED or DV vs. IPRED plots, observations are evenly scattered around the line of unity,
and the loess regression line closely approximates the line of unity. In the bottom two plots,
residuals are evenly distributed around the horizontal line of zero. Overall, no systematic
bias is detected from the diagnostic plots.
Out of the 1000 bootstrap runs, 919 runs (91.9%) minimized successfully. Results
from the successfully converged bootstrap runs were used to derive the median and 95%
confidence intervals for PK parameter estimates (Table 4.6). The final PK parameters were
very similar to the bootstrapped median values and fell within the 95% confidence interval,
which supported the stability of the model.
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The prediction-corrected VPC plot of the final model is presented in Figure 4.3.
The observed median, 5% and 95% concentrations all fell within their corresponding 95%
prediction intervals simulated based on the final PK model, which supported the adequacy
of the model and the lack of model misspecification.

Table 4.6 Comparison of parameter estimates and bootstrap results of final clonidine
model
Original Dataset
Bootstrap Resampling
Model Parameter
Estimate
95% CI*
Median
95% CI#
Structural and Covariate Model
CL/F per 70 kg (L/hr)
13.6
12.0-15.2
13.6
11.6-15.5
V/F per 70 kg (L)
385
339-431
385
328-443
-1
Ka (hr )
0.905
0.576-1.23
0.899
0.543-1.48
HILL
0.471
0.0633-0.879
0.464
0.141-1.08
T50 (day)
6.35
5.98-6.72
6.42
4.66-7.73
Interindividual Variability
ω2CL
0.128
0.0682-0.188
0.121
0.0412-0.187
2
ω HILL
3.68
0.642-6.718
3.73
1.20-10.2
Residual Variability
σprop
0.265
0.225-0.305
0.263
0.224-0.303
*
Calculated from parameter estimate±1.96*SE. #Derived from 2.5th and 97.5th percentiles
based on distribution of parameters generated from bootstrap runs.
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Figure 4.2 Diagnostic plots of the final clonidine model. In the top two panels, the grey
solid line represents the line of unity. The blue line in all four plots represents the loess
regression line. DV, dependent variable (clonidine concentration) in ng/mL. PRED,
population predicted value in ng/mL. IPRED, individual predicted value in ng/mL.
CWRES, conditional weighted residuals.
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4.2.2.4 Dose Simulations
According to the current protocol, patients who received clonidine as the primary
treatment were started on 1 µg/kg every 3 hours of oral clonidine, and if this dose was not
adequate (i.e., symptom stabilization was not achieved based on Finnegan score), dose was
escalated by 25% of the initial dose every 12-24 hours until attainment of symptom
stabilization. The maximum dose allowed in the study protocol was 2 µg/kg every 3 hours.
As one of the main goals in improving the care of NAS patients is to shorten their length
of hospital stay, one important way to optimize dosing regimen is to design an initial
dosing regimen to increase the probability of achieving early symptom stabilization and
decrease the need for dose escalation.
As shown in Figure 4.4, the vast majority of the patients (34 out of 40) required
dose increase of primary clonidine treatment during their stay, and most of the first dose
escalation occurred within 20 hours of treatment initiation. This observation pointed to the
suboptimal performance of the initial dosing regimen.
Simulation results of the original starting dose (1 µg/kg every 3 hours) and two
newly proposed regimens (1 µg/kg every 3 hours with a loading dose of 3 µg/kg, 1 µg/kg
every 3 hours with a loading dose of 5 µg/kg) are presented in Figure 4.5. The median
simulated concentrations were plotted against a minimum target concentration of 1 ng/mL.
As shown in the upper panel, with the original starting dose it would require approximately
20 hours to reach 1 ng/mL. This delay in reaching the effective level likely explained the
need for dose escalation in the majority of the subjects. In comparison, addition of a 3
µg/kg loading dose would shorten the time to target concentration to around 14 hours,
while addition of a 5 µg/kg loading dose would further decrease the time needed to around
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6 hours. The addition of loading dose would not change the steady state concentration, and
as shown in the lower panel of Figure 4.5, the median concentrations generated from all
three dosing regimens gradually converged.

Figure 4.3 The prediction-corrected visual predictive check plot of the final clonidine
model. The solid red line is the median prediction-corrected observed plasma
concentration, and the dashed red lines represent the 5% and 95% of the predictioncorrected observed concentration. The semitransparent red area represents the 95%
confidence interval for the model-predicted median, and the semitransparent blue areas
represent the 95% confidence intervals for the model predicted percentiles. The blue
circles represent prediction-corrected observed plasma concentrations.
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Figure 4.4 Histograms of number of dose increases needed and time to first dose increase
in clonidine-treated subjects.
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Figure 4.5 Simulated median clonidine concentrations by different dosing regimens. The
horizontal dotted line represents a minimum target concentration of 1 ng/mL.
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4.2.3

Discussion

In this analysis, a population PK model of clonidine was constructed from 40 NAS
patients. A one-compartment model was found to adequately describe the concentrationtime profile. Covariates incorporated in the final model included weight on CL/F and on
V/F by allometric scaling, and PNA on CL/F described by a sigmoidal maturation model.
Model performance was evaluated by routine diagnostic plots, bootstrap resampling and
prediction-corrected VPC, which demonstrated the adequacy of the final model in
describing the concentration data. The standardized apparent clearance and apparent
volume were estimated to be 13.6 L/h and 385 L, respectively. Given that the oral
bioavailability of clonidine is very high, these estimates were close to clearance and
volume estimates from adult IV studies.157,161
As mentioned in the introduction section, prior to this study there had been two
PopPK studies describing clonidine disposition in pediatric patients. The study by Potts et
al. used 380 observations from 72 children with a mean age of 4 and age range between 1
week to 14 years. A two-compartment model was used with allometric scaling of PK
parameters and asymptotic exponential maturation of clearance based on PNA.159 Another
study by Xie et al. had a very similar patient population compared to this study: neonates
with NAS. Using concentration data from 36 neonates (aged 1 to 25 days), they
constructed a one-compartment model with allometric scaling of PK parameters and
sigmoidal maturation of clearance based on PNA, a model very similar to what was
reported here.107 The standardized clearance and steady state volume estimates reported
by Potts et al. were 14.6 L/h and 181.5 L.159 Xie et al. reported estimates of standardized
apparent clearance and apparent volume to be 15.2 L/h and 391 L.107 While their models
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and ours reported similar estimates for standardized clearance, there were differences in
the model-predicted clearance maturation trajectories. Both the model by Xie et al. and
our model predicted a rapid maturation process of clearance in early postnatal period using
sigmoidal maturation functions. Based on these two models, maturation half-life was
estimated to be ~ 4 days and 6 days, respectively; standardized clearance would reach 70%
of adult value at PNA of 28 days and 38 days, respectively. In contrast, work by Potts et
al. predicted that the standardized clearance would be 26.2% of adult value at birth, and
the maturation process would be slower with a maturation half-life of 25.7 weeks (180
days).159 Figure 4.6 compares the predicted clearance maturation trajectories between this
work and the other two models. The predicted standardized clearance value based on this
model lies between the predicted values from the other two models. Predicted trajectory
of apparent clearance from our model was more similar to that predicted from the model
by Xie et al., probably because both studies were based on data from the same patient
population (i.e., neonates with NAS).107
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Figure 4.6 Predicted change of clonidine standardized clearance as a function of
postnatal age. Clearance value has been standardized to 70 kg adults using allometry. Our
model is compared with the models by Potts et al. and Xie et al.107,159
In the covariate model development process, allometric scaling was incorporated a
priori to explain the effect of weight on PK parameters using theory-based allometric
exponents of ¾ for clearance and 1 for weight. Though empirical allometry was used in
some other studies, empirical estimates of allometric exponents have been found to be
imprecise and have low predictive value when derived from datasets with limited sample
size and weight distribution.135 As proposed in the “standardized” PK approach by Holford
et al.,135 clearance maturation as a function of age was evaluated after the weight effect
was accounted for. Anderson and Holford proposed that as physiologically maturation
process of clearance starts developing before birth, PMA would be a superior predictor of
clearance maturation than PNA.132 Nevertheless, PNA was found to be a more superior
age descriptor of maturation changes in clonidine clearance than PMA in all three studies
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presented. In this study, the limited distribution of gestational age (36-41 weeks) could
have contributed to limited utility of PMA in the modeling process, but underlying
physiological development in relation to CYP2D6-mediated elimination perhaps offers a
better explanation.
As mentioned earlier, CYP2D6 metabolism and renal excretion each contributes
about half to clonidine clearance. Rhodin et al. pooled data on GFR from studies covering
subjects ranging from very premature neonates to adults to study renal function
maturation.137 Using a population PK approach with allometric scaling and sigmoid
hyperbolic function to describe the relationship between GFR and PMA, they predicted
that the GFR standardized to 70 kg adults increased from 35% of adult value at birth to
half of adult value at 47.7 post-menstrual weeks (7.7 postnatal weeks), and reached 90%
of adult value at 1 year of postnatal age.137 On the other hand, CYP2D6 expression levels
significantly increase within a few weeks after birth to mature levels.134 In a study on a
large and diverse set of pediatric liver samples, Stevens et al. reported that the levels of
CYP2D6 in fetal liver samples were very low but increased significantly after the first
week of life.163 Consistent with the findings by Treluyer et al., Stevens et al. reported that
gestational age was unlikely a significant determinant of CYP2D6 activity, and certain
birth-dependent process was likely an important contributor to CYP2D6 maturation.163,174
It therefore appears that our model-predicted age-dependent change in clonidine clearance,
after adjusting for body weight, more closely mimics the developmental change in
CYP2D6 expression than renal function. As there exists two concurrent maturation
processes, this finding could imply that one maturation process (CYP2D6 maturation)
could dominant over the other one (renal function development) within this specific age
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range. Nevertheless, a better modeling approach would be to evaluate the effect of renal
function on total clearance by estimating GFR using e.g., the Schwartz formula.175
However, as only a few of the study subjects had serum creatinine measured, renal function
could not be taken into account in the modeling process. This is one important limitation
of this analysis.
Our study was the first to evaluate the potential effect of CYP2D6 metabolizer class
on clonidine disposition in neonates. CYP2D6 is a highly polymorphic enzyme, and there
are more than 90 known allelic variants.176 Therefore, an important question is how
genotypes may affect CYP2D6 expression in early stage of life. Stevens et al. found that
both age and genotypes were significantly associated with CYP2D6 expression levels in
postnatal liver samples.163 Additionally, Blake et al. used O-methylation of
dextromethorphan (mediated by CYP2D6) as a marker for CYP2D6 activity in infants,
and found that the activity level was consistent with genotype by 2 weeks of age.177 In our
analysis, CYP2D6 metabolizer class (EM vs. IM/PM) did not significantly affect clonidine
clearance. This negative finding could be due to the very low frequency of IM/PM among
this relatively homogeneous study population, which also implied that a much larger
sample size would be needed to detect the effect of CYP2D6 metabolizer class if it is
indeed significant.
One of the most important goals of population modeling and simulation is to inform
the selection of safe and effective dosing regimen. Based on the final model, the
elimination half-life for a neonate aged 2.1 days with weight of 3 kg (the median value at
baseline) was estimated to be 24 hours. For a typical neonate aged 12.4 days with weight
of 3.3 kg (the median value at all observations), the estimated elimination half-life was 16
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hours. The prolonged half-life of clonidine translated to observed delay in the onset of
efficacy. A study by Arenas-Lopez et al. found that adequate sedation was achieved in
majority of pediatric patients with steady state clonidine levels between 1 and 1.8
ng/mL.178 While the maximum safe concentration is undefined, clinical use of clonidine
in pediatric patients is mostly safe, and concentrations up to 6 ng/mL were reported in the
studies on mechanically ventilated children.179 Using the original starting dose, it took
about 20 hours for median simulated concentration to reach the minimum target level of 1
ng/mL. This long delay at least partially explained the need for early dose escalation
(within a day of treatment initiation) in most clonidine subjects, and any dose escalation
would prolong the length of treatment due to the slow weaning phase specified in the
dosing protocol. Simulation studies showed that addition of a loading dose could
effectively lower this delay in onset and likely decrease the need for early dose escalation,
and ultimately contributing to reduction in the length of treatment. Additionally, the dosing
regimen could be further improved by lengthening the dosing interval while maintaining
the same total daily dose, as the fluctuation in concentration was small given the long halflife of clonidine.
In summary, a PopPK model was successfully constructed for clonidine in NAS
patients. Postnatal age and weight were significant covariates on clonidine disposition, and
the model predicted that standardized clearance matured rapidly after birth. The significant
delay in onset of efficacy contributed to need for dose escalation early on, and simulations
showed that addition of a loading dose could effectively shorten this delay and likely
decrease the need for dose escalation.
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4.3

Morphine Population Pharmacokinetic Modeling
4.3.1

Methods

4.3.1.1 Trial Subjects and Sample Collection
Subjects enrolled in the No-POPPY trial (NCT03396588) from the start of trial
(December 2017) to February 2020 with PK samples collected were included in this
analysis. Details of the trial design were discussed in Section 1.6. Subjects randomized to
the morphine treated group received morphine 0.5 mg/mL oral solution, which was
compounded by the hospital pharmacy from morphine concentrate solution. Procedures of
sample collection and processing are described in Section 4.2.1.2.
4.3.1.2 SNP Genotyping
Patient DNA samples were genotyped for the ABCC3 -211C>T SNP (assay
C__27829307_10) and four SNPs in the OCT1 gene (OCT1*2, *3, *4, and *5) based on
the nomenclature from Tzvetkov et al.180 The allele information and TaqMan Assay ID for
OCT1*2-*5 are listed in Table 4.7. OCT1 alleles that were not OCT1*2-*5 were defaulted
to OCT1*1. Subjects were subsequently classified into three groups based on the presence
of these OCT1 variants: wild-type (OCT1*1/*1), heterozygote (OCT1*1/*2-*5) and
homozygote (OCT1*2-*5/*2-*5).165
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Table 4.7 OCT1 polymorphisms tested in morphine-treated subjects
SNP*
dbSNP
Nucleotide change Protein change
TaqMan Assay
OCT1*2

rs72552763

1260GAT>del

Met420del

C__34211613_10

OCT1*3

rs12208357

181C>T

Arg61Cys

C__30634096_10

OCT1*4

rs34059508

1393G>A

Gly465Arg#

C__30634080_20

OCT1*5

rs34130495

1201G>A

Gly401Ser

Custom assay$

*

The nomenclature of these four SNPs is based on Tzvetkov et al.180 Other nomenclatures
have been used in the literature.
#
Gly465Arg always occurs in a haplotype with the Met420del.
$
Design of the custom assay:
Forward primer sequence (TTCATAGCCCTCATCACCATTGAC), reverse primer
sequence (AATTTGACATGGCCATGGG), reporter 1 (VIC) sequence
(ATGCGGCTCACGCG), reporter 2 (FAM) sequence (ATGCGGCCCACGCG)
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4.3.1.3 Dataset Assembly
Dataset assembly was conducted as described in Section 4.2.1.4. The dosing
amount recorded in volume (mL) in the EHR was first converted to amount (of morphine
sulfate) in µg, which was then converted to equivalent amount in morphine in µg in data
processing. Morphine concentrations and M3G/M6G concentrations were manually added
into the dataset as dependent variables. M3G/M6G were subsequently converted to
morphine equivalent in morphine-metabolite model development. Demographics and
clinical factors described in Section 4.2.1.4, as well as genetic factors (ABCC3 −211C>T
genotype and OCT1 class) were incorporated into the dataset. Dataset merging and
manipulation steps were performed in R (ver. 3.6.2, The R Foundation for Statistical
Computing, Austria) under R Studio environment (ver. 1.2.5019).
4.3.1.4 Population PK Model Building
All modeling steps were performed in NONMEM and PsN on original
concentration data. Plasma concentrations below the lower limit of quantification (BQL)
were not reported, but the associated observation times were labeled and retained in the
dataset. Due to the relatively high frequency of BQL morphine observations, conditional
Laplacian estimation using the M3 method proposed by Beal et al. was used as the
estimation method.181 Specifically, M3 method treats BQL observations as fixed-point
censored observations. It fits the model to all observations, and the likelihoods for BQL
observations are calculated from the likelihoods that these observations are truly BQL.181
Exploratory graphs were generated using ‘ggplot2’ package in R.
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4.3.1.4.1 MORPHINE MODEL DEVELOPMENT
The process of base model development was described in Section 4.2.1.5.1.
Covariate model development started with a priori incorporation of allometric scaling into
PK parameters using fixed allometric exponents (0.75 on clearance terms and 1 on volume
terms) following Equation 4. Subsequently, covariate effect was explored on PK
parameters whose eta shrinkage were relatively small (<30%).172,173
Pharmacokinetics of morphine in pediatrics have been relatively well studied.
Previous modeling efforts showed that allometric scaling combined with sigmoidal
maturation model using PMA on CL provided good predictive ability, and the maturation
half-life was estimated to be around 54-58 post-menstrual weeks.152,182 Due to the limited
PMA distribution in our study subjects, current data would fail to support an empirical
sigmoidal maturation model with a physiologically meaningful maturation half-life
estimate. As shown in Figure 4.7, within the narrow range of PMA seen in this study, the
relationship between model-predicted standardized clearance and PMA approximated a
linear relationship. As previous studies have shown that morphine clearance continues to
mature after birth, only PNA and PMA were evaluated as age measures in univariate
analysis. Both PMA and PNA were evaluated on CL using a centered linear model
(Equation 10). PMA was also evaluated in a sigmoidal maturation function (Equation 5)
using fixed values of the hill coefficient and maturation half-life reported by Holford et al.
and Knosgaard et al.152,182
𝑊𝑊𝑊𝑊𝑖𝑖 𝜃𝜃𝑒𝑒𝑒𝑒𝑒𝑒
𝜃𝜃𝑖𝑖 = �𝜃𝜃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 + 𝜃𝜃𝑐𝑐𝑐𝑐𝑐𝑐 × �𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖 − 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(𝐶𝐶𝐶𝐶𝐶𝐶)�� �
× 𝑒𝑒 𝜂𝜂𝑖𝑖 (10)
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠
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Figure 4.7 Predicted age-dependent changes in standardized morphine clearance based on
previously published studies.
Categorical variables (gender, preterm birth, mode of delivery, race, ABCC3
−211C>T genotype and OCT1 class) were tested on PK measures following Equation 7.
The genetic factors were treated as dichotomous variables by assuming the relationship
reported by Venkatasubramanian et al.166 Covariate selection process was the same as
described in Section 4.2.1.5.2.
4.3.1.4.2 EXPLORATORY MORPHINE-METABOLITE MODEL DEVELOPMENT
The metabolite PK was modeled by adding an additional compartment for each
metabolite to the selected morphine base model. The residual error selected in the
morphine model development was applied in metabolite modeling. Models were specified
using general linear systems of differential equations with the ADVAN5 TRANS1
subroutine. In a previous morphine-metabolite PK study in pediatric patients, inclusion of
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direct morphine clearance (clearance unaccounted for by M3G and M6G formation
clearance) did not improve model prediction.183 Therefore, in this analysis, total apparent
morphine clearance CLMOR/F was assumed to be the sum of M3G and M6G formation
clearance, and was parameterized in terms of FM3G (fraction of morphine converted to
M3G) (Figure 4.8). Allometric scaling was applied to all CL and V terms. To ensure model
identifiability, apparent volumes of M3G and M6G metabolite compartments were
parameterized as being equal to the apparent volume of the parent central compartment.183
The IIV terms retained in the morphine-only model were included in the initial
model building process. As extensive correlation was expected between the IIV on the two
metabolite elimination clearance terms, CLM3G/F and CLM6G/F, a shared eta approach was
used as follows:172
𝑊𝑊𝑊𝑊𝑖𝑖 0.75 𝜂𝜂
𝑒𝑒 𝑀𝑀3𝐺𝐺𝐺𝐺 (11)
𝐶𝐶𝐶𝐶𝐶𝐶3𝐺𝐺/𝐹𝐹𝑖𝑖 = 𝐶𝐶𝐶𝐶𝐶𝐶3𝐺𝐺𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 �
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠

𝐶𝐶𝐶𝐶𝐶𝐶6𝐺𝐺/𝐹𝐹𝑖𝑖 = 𝐶𝐶𝐶𝐶𝐶𝐶6𝐺𝐺𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 �

𝑊𝑊𝑊𝑊𝑖𝑖 0.75 (𝜂𝜂
𝑒𝑒 𝑀𝑀3𝐺𝐺𝐺𝐺 ×𝜃𝜃𝑠𝑠ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎) (12)
�
𝑊𝑊𝑊𝑊𝑠𝑠𝑠𝑠𝑠𝑠

where 𝜃𝜃𝑠𝑠ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 is the variance scale factor on shared eta. IIV on CLM3G/CLM6G was

retained in model if it was well estimated (CV<50%) and eta shrinkage was small.
Covariate-parameter relationship selected in the morphine only model was explored in the
metabolite-parent model.
4.3.1.4.3 MODEL EVALUATION
Evaluation of morphine-only model was as described in Section 4.2.1.5.3. Due to
the computational burden, evaluation of the exploratory morphine-metabolite model was
by routine diagnostic plots only.
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Figure 4.8 Scheme of the exploratory morphine-metabolite model.
4.3.2

Results
4.3.2.1 Demographics

A total of 189 PK observations from 41 subjects were included in the analysis. Of
the 189 observations, 68 morphine observations, 1 M3G observation and 39 M6G
observations were below the LLOQ. All the LLOQ observations were incorporated in the
analysis using the M3 approach.181
Subject demographics at baseline and at PK observations are presented in Table 4.8,
which are very similar to that of the clonidine subjects. The median (range) of PNA at PK
observations was 11.3 days (2.39-63.4 days). Distribution of OCT1 class and ABCC3 211C>T genotypes is presented in Table 4.9. For OCT1 class, 56% were classified as wildtype, 29% and 15% were classified as heterozygous and homozygous, respectively. This
distribution was similar to what was reported by Fukuda et al. and Venkatasubramanian et
al.165,166 For ABCC3 −211C>T, 10% of subjects carried the CC genotype, and the
remaining half of the subjects carried either the CT or TT genotype.
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Table 4.8 Demographics for morphine subjects in population PK model development
Baseline demographics (41 subjects)
Count (%) or Mean (SD)
Infant sex, male

24 (59%)

Race
Caucasian

36 (88%)

Multiple

5 (12%)

Preterm birth (GA<38 weeks)

15 (37%)

Mode of delivery, vaginal birth

20 (49%)

Birthweight (kg)

3.09 (0.531)

Postnatal age (PNA, day)

2.52 (1.35)

Gestational age (GA, day)

268 (9.05)

Post-menstrual age (PMA, day)

271 (9.34)

Demographics at PK obs (n=189)

Median (Range)

Weight (kg)

3.10 (1.85-6.08)

Postnatal age (PNA, day)

11.3 (2.39-63.4)

Gestational age (GA, day)

268 (249-286)

Post-menstrual age (PMA, day)

280 (252-348)
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Table 4.9 Distribution of OCT1 class and ABCC3 -211C>T genotypes among morphine
subjects
OCT1 Genotype
Class

Genotype

N (%)

Wild-type

OCT1*1/*1

23 (56%)

OCT1*1/*2

8 (20%)

OCT1*1/*3

3 (7%)

OCT1*1/*5

1 (2%)

OCT1*2/*2

5 (12%)

OCT1*3/*4

1 (2%)

Heterozygous

Homozygous

ABCC3 -211C>T
Genotype

N (%)

C/C

4 (10%)

C/T

18 (44%)

T/T

19 (46%)

The observed concentration-time profiles for morphine and metabolites are shown
in Figure 4.9, where the dashed vertical lines represent the typical dosing interval. As
shown on the top left plot, morphine concentrations taken after 4 hours post the final dose
are all below the LLOQ, likely due to the short half-life of morphine. In contrast, only 1
M3G concentration is below the LLOQ. Looking at the dose-normalized plots,
observations of morphine/M3G/M6G taken beyond three hours after dose show a
decreasing trend over time.
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Figure 4.9 Observed concentration-time profiles of morphine and its major metabolites.
All observations are included. On the left from top to bottom: concentration (ng/mL) vs.
time after dose for morphine, M3G, M6G. Black horizontal line represents lower limit of
quantification (1 ng/mL). On the right from top to bottom: dose normalized concentration
(1/L) vs. time after dose for morphine, M3G, M6G. Vertical dashed lines are marked at 3
hours (the typical dosing interval).
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4.3.2.1 Morphine Model Development
Fitting one-compartment model with first-order absorption and elimination was
successful. When choosing between different error models, additive error model provided
the worst fit based on OFV. While mixed error and proportional error models resulted in
the same OFV, the estimate of additive error approached 0 in the mixed error model.
Therefore, a proportional error model was selected. Similar to the clonidine model building
process, fitting with two-compartment model resulted in values of Q and/or V2 that were
approaching 0 without improvement of the OFV. Therefore, subsequent covariate model
development was based on a one-compartment model with proportional error. Starting
with this base model without any IIV, addition of IIV on CL/F significantly decreased the
OFV by 50.3; IIV on CL/F was well estimated with small eta shrinkage (11.2%). Further
addition of IIV on V/F did not significantly change the OFV, and this IIV term was poorly
estimated (CV=92%). Therefore, only IIV on CL/F was included in the selected onecompartment model as the base model (OFV = 476.2). Parameter estimates for the base
model are shown in Table 4.10.
Table 4.10 Parameter estimates for the base morphine model (OFV = 476.2)
Model Parameter
Estimate
Standard Error
RSE (%)
Structural Model
CL/F (L/hr)
4.61
0.312
6.77
V/F (L)
6.80
0.777
11.4
Ka (hr-1)
0.537
0.0763
14.2
Interindividual Variability
ω2CL
0.112
0.0365
32.6
Residual Variability
σprop
0.450
0.0336
7.47
In covariate model development, allometric scaling was first incorporated with
fixed allometric exponents, which decreased the OFV to 442.8 (∆OFV=-33.4; p<0.01). As
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mentioned in Section 4.3.1.4.1, four models incorporating PMA on PNA onto CL/F were
tested, and their comparison is presented in Table 4.11.

Table 4.11 Univariate analysis of age on morphine apparent clearance
Model description
OFV
Number of
parameters

AIC

PNA on CL/F (centered linear model) + IIV on
CL/F

359.9

6

371.9

PMA on CL/F (centered linear model) + IIV on
CL/F

374.4

6

386.4

#

PMA on CL/F (sigmoidal maturation) + IIV on
CL/F

404.6

7

418.6

*PNA on CL/F (sigmoidal maturation model) + IIV
on CL/F

406.4

7

420.4

#

Maturation half-life and hill coefficient fixed to 54.2 weeks (379 days) and 3.92182
*Maturation half-life and hill coefficient fixed to 58.1 weeks (406 days) and 3.6152
As shown in Table 4.11, centered linear model based on PNA/PMA provided a
better fit of the data over sigmoidal maturation model with fixed maturation half-life and
hill coefficients from previous reports. Based on AIC, PNA on CL/F with a centered linear
model was selected as the best age covariate model.
Univariate analysis with categorical variables, however, did not reveal any
statistically significant covariate-parameter relationship. Though genetic factors were not
shown to be statistically significant on apparent clearance (∆OFV = -2.5 and -1.0 for OCT1
class and ABCC3 -211C>T respectively, p>0.05) exploratory box plots were graphed to
assess the relationship between unexplained interindividual variability in apparent
clearance and OCT1 class or ABCC3 -211C>T. Figure 4.10 shows a clear decreasing trend
in interindividual variability in apparent CL as the number of defective OCT1 alleles
increased, which was consistent with previous finding. However, for ABCC3 -211C>T the
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change in interindividual variability of apparent clearance with the number of C allele at
the ABCC3 gene locus was less clear, partially due to the small number of CC genotype
carriers and large observed variability.

Figure 4.10 Relationship between interindividual variability in morphine apparent
clearance and OCT1 class and ABCC3 -211C>T genotype at all observations. In top
panel: 0 = wild-type, 1 = heterozygous, 2 = homozygous. In bottom panel: 0 = C/C, 1 =
C/T, 2 = T/T.
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The final model selected was a one-compartment model with first-order absorption
and elimination, incorporating allometric scaling and PNA on CL/F with a centered linear
function. IIV on CL/F was incorporated, and residual variability was modeled as
proportional error. The following equations summarize the final model:
𝐶𝐶𝐶𝐶
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑘𝑘𝑘𝑘) 0.75
= (57.8 + 3.11(𝑃𝑃𝑃𝑃𝑃𝑃 − 11.3)) × �
(13)
�
𝐹𝐹
70
𝑉𝑉
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑘𝑘𝑘𝑘)
= 167 × �
� (14)
𝐹𝐹
70

Final model parameter estimates are summarized in Table 4.12. All model
parameters were estimated with good precision. Compared with the base model, the
incorporation of PNA decreased ω2CL by about 19%, and decreased residual error from 45%
to 29%.
Table 4.12 Parameter estimates for the final morphine model (OFV = 359.9)
Model Parameter
Estimate
Standard Error
RSE (%)
Structural and Covariate Model
CL/F per 70 kg (L/hr)
57.8
4.05
7.00
V/F per 70 kg (L)
167
5.50
3.29
-1
Ka (hr )
0.568
0.0759
13.4
PNA on CL/F (linear model)
3.11
0.516
16.6
WT on CL/F
0.75 (fixed)
WT on V/F
1 (fixed)
Interindividual Variability
ω2CL
0.0912
0.0154
16.9
Residual Variability
σprop
0.290
0.0224
7.72
Routine diagnostic plots of the final model are demonstrated in Figure 4.11. In the
DV vs. PRED or DV vs. IPRED plots, the LOESS regression lines closely proximate the
line of unity. In the residual plots, no distinguishable patterns can be identified. These plots
supported the adequacy of the model and a lack of systematic bias.
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Figure 4.11 Diagnostic plots of the final morphine model. In the top two panels, the grey
solid line represents the line of unity. The blue line in all four plots represents the loess
regression line. DV, dependent variable (morphine concentration) in ng/mL. PRED,
population predicted value in ng/mL. IPRED, individual predicted value in ng/mL.
CWRES, conditional weighted residuals.
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Out of the 1000 bootstrap runs, 751 runs (75.1%) minimized successfully, which
likely reflected the relative numerical complexity using the M3 method. Bootstrap runs
that were successfully minimized were used to generate the median and 95% confidence
intervals for PK parameter estimates (Table 4.13). The final PK parameters were very close
to the bootstrapped median and located within the bootstrapped 95% confidence interval.

Table 4.13 Comparison of parameter estimates and bootstrap results of the final morphine
model
Original Dataset
Bootstrap Resampling
*
Model Parameter
Estimate
95% CI
Median
95% CI#
Structural and Covariate Model
CL/F per 70 kg (L/hr)
57.8
49.9-65.7
58.3
50.7-67.2
V/F per 70 kg (L)
167
156-178
168
145-288
-1
Ka (hr )
0.568
0.419-0.717
0.560
0.411-0.682
PNA on CL/F
3.11
2.10-4.12
3.19
2.17-4.31
Interindividual Variability
ω2CL
0.0912
0.0610-0.121
0.0880 0.0434-0.132
Residual Variability
σprop
0.290
0.246-0.334
0.283
0.234-0.332
*
#
th
Calculated from parameter estimate±1.96*SE. Derived from 2.5 and 97.5th percentiles
based on distribution of parameters generated from bootstrap runs.
The prediction-corrected VPC plot of the final model is presented in Figure 4.12.
Slight underprediction was seen at the early timepoints (i.e., high concentrations).
Otherwise the observed median, 5% and 95% concentrations all fell within their
corresponding 95% prediction intervals simulated based on the final PK model.
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Figure 4.12 The prediction-corrected visual predictive check plot of the final morphine
model. Top plot: The solid red line is the median prediction-corrected observed plasma
concentration, and the dashed red lines represent the 5% and 95% of the predictioncorrected observed concentration. The semitransparent red area represents the 95%
confidence interval for the model-predicted median, and the semitransparent blue areas
represent the 95% confidence intervals for the model predicted percentiles. The blue
circles represent prediction-corrected observed plasma concentrations. Bottom plot: The
blue line shows the observed trend on the proportion of LLOQ observations versus time,
while the semitransparent blue area represents the corresponding model-predicted 95%
confidence interval.
4.3.2.2 Exploratory Morphine-metabolite Model Development
A parent-metabolite model described in Section 4.3.1.4.2 was fitted, incorporating
a centered linear model of PNA on CLMOR/F (the covariate-parameter relationship selected
in the morphine model development). Model convergence was successful, and the
parameter estimates are summarized in Table 4.14. All parameters were well estimated
with RSE%<50%. The estimate of FM3G was close to previously reported value in
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pediatric studies.182 Of note, both of the VMOR/F and Ka estimates were smaller than the
values estimated in the morphine-only model.
Based on the DV vs. IPRED plots in Figure 4.13, the morphine model mostly
provided a good fit to the data, but had the tendency to overpredict morphine
concentrations at high levels. For both M3G and M6G the model had the tendency to
underpredict high concentrations. Model performance needs to be improved with more
data and further exploration into different model assumptions and incorporation of other
covariates.
Table 4.14 Parameter estimates of the exploratory morphine-metabolite model
Model Parameter
Estimate
RSE (%)
Structural and Covariate Model
CLMOR/F per 70 kg (L/hr)
58.7
14.3
VMOR/F per 70 kg (L)
33.3
42.9
Ka (hr-1)
0.236
26.1
PNA on CL/F (linear model)
3.34
30.2
VM3G/F per 70 kg (L)
VMOR/F
VM6G/F per 70 kg (L)
VMOR/F
FM3G
0.833
3.43
CLM3G/F per 70 kg (L/hr)
8.44
5.77
CLM6G/F per 70 kg (L/hr)
7.00
16.4
Variance scale factor on shared eta
0.955
17.0
Interindividual Variability
ω2CLMOR
0.118
27.9
2
ω CLM3G
0.0467
26.3
Residual Variability
σprop,morphine
0.316
7.25
σprop,M3G
0.237
4.43
σprop,M6G
0.232
3.34
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Figure 4.13 Diagnostic plots (DV vs. IPRED) for exploratory morphine-metabolite
model. DV, dependent variable (plasma concentration in ng/mL for morphine, morphineequivalent plasma concentration in ng/mL for M3G/M6G). IPRED, individual predicted
value. Blue line represents LOESS regression line.
4.3.3

Discussion

In this analysis, a PopPK model was developed for morphine in neonates with NAS.
A one-compartment model with first-order absorption and elimination was selected as the
base model. After incorporation of allometric scaling, age (PMA/PNA) was found to be a
significant covariate on CL/F. Because data in our model did not support full estimation
of sigmoidal maturation process reported in previous studies, in this analysis centered
linear model was compared to sigmoidal maturation model with maturation half-life and
hill coefficient fixed to previously reported values. Based on the model selection criterion,
a centered linear model of PNA on CL/F was selected as the best age univariate model.
Screening of other factors did not identify any statistically significant covariates. Model
evaluation supported the predictive adequacy of the final model.
As a linear model was selected to describe the relationship between PNA and CL/F,
our model could not be safely extrapolated to subjects outside the age range observed in
this study. Based on the parameter estimates, at the median PNA observed in this study
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(11 days), the standardized apparent clearance was estimated to be 57.8 L/h. At the same
age (assuming gestational age of 280 days), the estimated standardized clearance was
between 16 and 20 L/h based on prior PK studies,182 which led to an estimate of
bioavailability between 28% to 35% in this study. This number was very similar to
bioavailability estimates in adults, while it was lower than the estimate of 48.5% by Liu et
al.154
The construction of an adequate PopPK model allowed us to evaluate the potential
effect of genetic factors on apparent morphine clearance, which was a novel aspect of this
analysis. Neither OCT1 class nor ABCC3 -211C>T genotype significantly improved
model fit, though a decreasing trend in unexplained individual variability in apparent
morphine clearance was observed with increased number of defective OCT1 alleles. While
looking at previous literature reports, Fukuda et al. were the first to show the OCT1 class
was a significant covariate on morphine clearance in children;165 however, this finding was
not reproduced in an extended study by Venkatasubramanian et al., who found that OCT1
class was a significant covariate on formation clearance of M3G but not on morphine
clearance.166 The latter study also reported that patients with CC genotype of ABCC3 211C>T had significantly higher M3G/M6G formation clearance (by improving the model
fit), but this genetic factor did not significantly affect morphine clearance.166 As the
M3G/M6G formation clearance contributes to the majority of morphine clearance, the lack
of significant association between these genetic variants and morphine clearance shown
by Venkatasubramanian et al. implied the limited magnitude of their impact on morphine
parent-metabolite disposition. The lack of association between OCT1 class/ABCC3 211C>T genotype and neonatal morphine clearance in this study could also be explained
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by ontogeny of the drug transporters. Prasad et al. reported that the protein expression of
OCT1 and ABCC3 in neonates is significant lower that in adults.184 Specifically, the
protein level of OCT1 in neonates is about only about one fifth of the level in adults, while
significant interindividual variability was observed for ABCC3 protein expression level in
neonates.184 These findings indicate that the effect of genotypes on the expression levels
of these transports could likely be confounded by their ontogeny.
Morphine is metabolized by UGT2B7 to M3G and M6G, therefore it would be
worthwhile to investigate the effect of UGT2B7 genotypes on morphine clearance.
However, such studies in neonates will be difficult to interpret due to the ontogeny of
UGT2B7. A previous study found that the abundance of UGT2B7 in neonatal liver
samples was only about 13% of adult levels, and it estimated that 50% adult abundance of
UGT2B7 was reached at 2.8 years of age.185 Study findings on the association between
UGT2B7 genotypes and morphine disposition in adults have been conflicting. Some
studies reported no relationship between UGT2B7 genotypes and disposition of morphine
and metabolites, while several others have linked some SNPs in UGT2B7 to meaningful
differences in morphine PK/PD outcomes.186 Zuppa et al. were the first to investigate the
potential effect of UGT2B7 polymorphisms on morphine-metabolite disposition in
children in a model-based exploratory analysis, but no significant relationship was
identified.186
In addition to a morphine-only model, an exploratory morphine-metabolite model
was fitted to the data. The only covariate included in this model was PNA on apparent total
morphine clearance. This model provided an adequate fit to morphine plasma
concentrations, while it had the tendency to underpredict M3G and M6G at high
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concentrations. However, due to the large interpatient variability and limited information
in the absorption phase, the parameter estimates for Ka and morphine apparent volume
were variable and highly dependent on model parameterization. Due to the limited sample
size and sparsity of sample collection, model assumptions needed to be simplified to
ensure the stability of the fitted model. With more samples available, additional model
assumptions could be attempted, including the addition of an intermediate compartment to
account for possible delay in the appearance of metabolites. Once a stable base parentmetabolite model was obtained, additional covariates could be screened on PK parameters.
Additionally, maturation pattern of metabolite elimination clearance and parent volume
could be explored.

4.4

Conclusion
Clonidine and morphine PopPK models were successfully constructed using PK

data from NAS patients. With both models, incorporation of allometric scaling
significantly improved model fit, and age was identified as a significant covariate. In
contrast, incorporation of prespecified genetic factors did not improve the model fit
significantly. The clonidine model was used to perform simulation studies in an effort to
improve upon the current dosing regimen. This modeling exercise identified the addition
of a loading dose as a potentially effective strategy to increase the probability of achieving
early symptom stabilization.
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CHAPTER 5. CONCLUSIONS
This work was based on clinical data and biospecimen collected from the NoPOPPY trial, which is primarily intended to compare the efficacy of morphine vs.
clonidine in treating NAS. This work aimed to address the following specific aims: 1)
investigate the relationship between SNPs in opioid receptors/stress response genes and
disease severity/treatment outcomes in NAS in genetic association analysis; 2) investigate
the relationship between SNPs that can potentially affect the PK of morphine/clonidine
and the disposition of these two drugs in population PK analysis; 3) use population PK
modeling and simulation to inform the optimization of dosing regimen.
In this work, the effect of genetic factors and clinical factors on disease severity
and drug disposition was investigated in genetic association analysis and in population PK
modeling (Figure 5.1). In SNP association analysis, several clinical factors, including
breastfeeding and concurrent exposure to other substances, were important predictors in
disease severity. In contrast to a previous report, the relationship between COMT 472G>A
or OPRM1 118A>G and LOS or other outcome measures was inconclusive. Clonidinetreated patients with TT genotype in GNB3 825C>T had an average length of stay that was
3.7 days shorter than those with CC/CT genotype (p=0.045); however, this association did
not meet experiment-wise significance. In population PK analysis, weight and age
significantly affected clonidine and morphine disposition, while effect of genetic factors
was nonsignificant. With both clonidine and morphine, the final PK model fitted observed
data reasonably well, and model evaluation showed a lack of systematic bias of the models.
Most importantly, simulation studies based on the final clonidine model showed that
addition of a loading dose could effectively shorten the delay in onset and likely decrease
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the need for early dose escalation, and ultimately contributing to reduction in the length of
treatment.

Figure 5.1 The interplay between genetic variants and PK/PD of treatment agents and
disease severity of NAS investigated in this work.
In this work, clinical factors appeared to be more important factors affecting drug
disposition and NAS severity/treatment outcomes than the genetic factors evaluated. This
conclusion could be limited by the presence of confounding factors, homogeneity of study
subjects, and relatively small sample size. Specific to population PK analysis, another
limitation existed with the reliance on sparse sampling and existence of large
interindividual variability. Nevertheless, the findings from this analysis can contribute to
the continuing effort in improving the care of NAS patients, especially by the use of
modeling and simulation in improving the dosing regimen of clonidine. Here we would
like to draw the attention to importance of optimizing dosing regimen of treatment agents
in NAS, which can be arguably equally important as identifying the optimal treatment
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agents. In the future, further prospective studies will likely inform how NAS treatment
regimens can be individualized based on clinical and/or genetic factors. For example, in
this study, we confirmed previous findings that NAS patients exposed to psychotropic
mediations underwent more prolonged withdrawal than those without such exposure, and
it would be worthwhile to investigate if these patients are more likely to benefit from
treatment by a certain opioid/non-opioid agent in future studies.
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